WO1994009127A2 - Supercoiled minicircle dna as as a unitary promoter vector - Google Patents

Supercoiled minicircle dna as as a unitary promoter vector Download PDF

Info

Publication number
WO1994009127A2
WO1994009127A2 PCT/US1993/009918 US9309918W WO9409127A2 WO 1994009127 A2 WO1994009127 A2 WO 1994009127A2 US 9309918 W US9309918 W US 9309918W WO 9409127 A2 WO9409127 A2 WO 9409127A2
Authority
WO
WIPO (PCT)
Prior art keywords
dna
promoter
transcription
gal
minicircle
Prior art date
Application number
PCT/US1993/009918
Other languages
French (fr)
Other versions
WO1994009127A3 (en
Inventor
Sankar L. Adhya
Hyon E. Choy
Original Assignee
The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services filed Critical The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services
Priority to AU54059/94A priority Critical patent/AU5405994A/en
Publication of WO1994009127A2 publication Critical patent/WO1994009127A2/en
Publication of WO1994009127A3 publication Critical patent/WO1994009127A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli

Definitions

  • the present invention relates to the production of supercoiled DNA minicircles which can be employed in vitro as a purified system to elucidate, for example, the various aspects of transcription, namely, initiation, elongation, and termination.
  • the present system closely resembles the molecular events which
  • occur in vivo and provides supercoiled DNA plasmid circles which carry only one promoter and which are considered as unitary promoter vectors.
  • Transcription involves the synthesis of RNA complementary to one strand of a DNA duplex, i.e. the "template” DNA, by the enzyme RNA polymerase. Transcription can be divided into three stages: (i) initiation, (ii) elongation and (iii) termination.
  • RNA polymerase to the double-stranded DNA.
  • RNA polymerase goes through at least four stages: (i) initial binding to the promoter (closed complex formation), (ii) isomerization of the closed complex to make the template strand available for base pairing with ribonucleotides (open
  • RNA polymerase undergoes a series of conformational changes that may be subject to regulation (7, 8).
  • In vitro transcription studies have shown the synthesis of considerable amounts of aborted transcripts of less than ten u nucleotides in length by many promoters. These results have underscored the importance of the idling and promoter clearance steps, in addition to closed and open complex formation, in the regulation of transcription initiation (6, 7).
  • the measurement of closed complex formation and subsequent open complex formation routinely uses an abortive initiation assay (9).
  • a regulatory assessment of the idling and the promoter clearance steps requires a transcription assay that employs a DNA template with a single promoter (i.e. a unitary promoter DNA template) so that both aborted and full length transcripts can be analyzed directly and simultaneously without interference by the products of other promoters. Since topological conformation of DNA can greatly influence the interactions between DNA and the transcriptional regulatory proteins (10-12, 41, 42) in that the efficiency of promoters is usually influenced by the degree of supercoiling, it would be relevant if the unitary promoter DNA template is supercoiled.
  • RNA polymerase or an activator protein binding
  • RNA polymerase or an activator protein binding
  • RNA polymerase isomerization or formation of the initial phosphodiester bonds
  • cAMP and its receptor protein (CRP) complex modulate the two promoters in opposite directions: cAMPoCRP complex stimulates the PI promoter but represses the P2 promoter. Repression of transcription from the two partially overlapping promoters, PI and P2, requires DNA looping generated by interaction of Gal repressor molecules bound to two operators, 0 E and 0 classroom which encompass the promoters and are separated by 11 B-DNA helical turns (23, 25, ° 38).
  • a DNA loop structure "locks" the RNA polymerase at the promoter, thereby establishing repression without any direct contact between repressor and RNA polymerase.
  • repression can be established through communication(s) between repressor and allosteric site(s) in the RNA polymerase as part of a nucleoprotein complex (8). Such contacts in the complex make RNA polymerase assume an idle form in repression. DNA looping juxtaposes the necessary components in a geometrically proper complex. 5 The study of the mechanism of repression of the lac promoter by
  • Lacl + repressor in purified systems has led to conflicting conclusions. Although it was originally believed that Lac repressor acts at the first step by inhibiting closed complex formation in the lac operon (47), it has been suggested that with wild type lac promoter, the repressor blocks a step after the formation of a closed promoter 0 complex (48). More specifically, from studying the cAMP independent f ⁇ cUV5 promoter at high concentrations of Lac repressor and RNA polymerase, Straney and Crothers (49) suggested that Lac repressor blocks the second step, the isomerization of the RNA polymerase-/ ⁇ c promoter complex to an open form.
  • ⁇ t - made is displaced from the template DNA and the DNA duplex reforms in that region.
  • the last base is added to the RNA chain, the RNA and RNA polymerase are released from the template DNA, and the DNA duplex reforms.
  • the present invention provides a DNA construct, i.e. a plasmid, which is designed to contain a selectable marker, such as ampicillin resistance (Amp); the bacterial and lambda attachment sites attB and attV (i.e. BOB and
  • mcs multiple cloning site
  • Ter transcriptional terminator sequence
  • a linear depiction of the relevant segment of 5 the plasmid construct is as follows: - Amp - BOB - mcs - gal - Ter - POP - .
  • the plasmid vector of the invention is introduced into a strain of bacteria which provides the lambda integrase (Int) protein and integration host factors (IHF).
  • the integrase gene which encodes the Int protein, is regulated by a temperature sensitive lambda repressor, c/857.
  • a temperature sensitive lambda repressor c/857.
  • no Int is produced at the 0 temperature of 32°C; however, at the temperature of 42°C, the c/857 repressor is denatured, allowing the expression of the integrase gene and the production of the Int protein.
  • host bacteria containing the plasmid vector of the invention are grown at 32°C. When the temperature is elevated to 42°C, the Int
  • 25 protein is expressed and a supercoiled DNA minicircle is created by the excision of the OB - mcs - gal - Ter - P' segment of the plasmid and is circularized by ligation of the two ends into an isolatable miniplasmid or "minicircle".
  • the Int protein and IHF catalyze the entire process by binding to BOB and POP. Since
  • the Int protein is somewhat heat labile, the temperature of the bacterial culture is returned to 32°C from 42°C for optimal yield.
  • the present invention serves as a means for the analysis of the precise and specific transcriptional properties of promoter and/or terminator present
  • the present invention also provides a method of * in vitro transcription using purified bacterial RNA polymerase, other transcription factors, and the DNA minicircle as a template.
  • the present invention is also applicable to the study of eukaryotic including mammalian, yeast and plant, transcription systems.
  • eukaryotic promoters, initiators, terminators and/or other transcriptional elements are used in the mcs of the plasmid vector and the appropriate eukaryotic enzymes and/or regulatory factors are supplied in the transcription reaction mixture.
  • the present invention is also applicable to the study of hybrid, homologous or heterologous, prokaryotic and eukaryotic transcription systems.
  • hybrid systems combinations of eukaryotic or prokaryotic promoters, initiators, terminators and/or other transcriptional elements are used in the mcs of the plasmid vector and the appropriate eukaryotic and prokaryotic enzymes and/or 5 regulatory factors are supplied in the transcription reaction mixture.
  • the invention generates supercoiled DNA miniplasmids, also called minicircles, which comprise only one promoter, or, as in the case of the gal operon, two overlapping promoters.
  • the DNA minicircles are frequently more efficient substrates for in vitro transcription than are linear DNA segments.
  • a 0 supercoiled miniplasmid with unique promoter(s) can avoid the use of oligonucleotides as primers which are required to analyze promoters from both linear and circular DNA templates which contain multiple promoters.
  • Another objective is to develop a DNA vector which would allow the simple detection and assay of the entire array of transcription products — both complete RNA, as well as aborted RNA oligomers, produced either by single cycle or by reiterative cycle reactions ⁇ in a purified system with supercoiled DNA.
  • the supercoiled DNA minicircles carrying only one promotor followed by a terminator can yield only one full-sized RNA of discrete size for easy identification.
  • a further objective of the invention to provide an in vitro unitary transcription system which does not have to use oligonucleotide primers to study transcription initiation.
  • the small DNA minicircles of the invention are used in such a manner, the appropriate enzymes and/or regulatory factors are supplied in an appropriate transcription/translation mixture.
  • Figure 1 Arrangement of the functional elements of the unitary promoter plasmid vector, pSA508.
  • the symbols and abbreviations as shown on the vector construct are as follows: Xbal: unique restriction site for endonuclease Xbal; BOB: bacterial attachment site attB'OB; mcs: multiple restriction endonuclease sites for cloning; Ter: transcription termination signal; POP: lambda phage attachment site attP'OP; Hindlll: unique restriction site for endonuclease Hindlll; and Amp: gene encoding ampicillin resistance.
  • Figure 2 DNA profiles of plasmid pSA508 before and after Int/IHF-mediated in vivo recombination displayed on a 1.0% agarose gel.
  • Lane 1 shows the 1 kb ladder (BRL).
  • Lane 2 plasmid DNA before recombination.
  • Lanes 3 and 4 DNA profile of the recombination products.
  • Lane 4 was loaded with five fold more DNA sample than lane 3 to make the minicircle product "a" clearly visible.
  • Lane 5 the monomer DNA minicircle after purification. Arrows: a, monomer minicircle; b, the larger product circle; c, a circle with two units of larger product circle; SI, monomer substrate; and S2, dimer substrate.
  • FIG. 3 gal promoter of E. coli in the minicircle generated from pSA509.
  • O E and O represent external and internal operator, respectively; Ter is the transcription terminator.
  • Figure 4 Effect of cAMP concentrations on transcription using the vector minicircle (from pSA508) or gal minicircle (from pSA509) as template.
  • CRP was present at 100 nM.
  • Transcription products were analyzed on an 8% (A) and on a 25% (B) urea-polyacrylamide gel.
  • Lanes 1-5 in A and 1-5 in B were loaded with RNA made from vector minicircle; lanes 6-10 in A and 6-10 in B contained RNA made from gal promoter containing minicircle.
  • the full-length transcripts on the 8% gel were quantified using a beta-scanner, and the total counts per minute (cpm) of each band were plotted against cAMP concentrations (C).
  • the open circles represent full-length RNA made from PI; the closed circles represent full-length RNA made from P2.
  • Figure 5 Rate of gal RNA synthesis.
  • a reaction mixture containing gal promoter DNA template and RNA polymerase was preincubated at 37°C for 5 min after which heparin was added to 100 ⁇ g/ml. Transcription reactions were initiated by the addition of nucleoside triphosphate substrates 1 minute after heparin challenge and were terminated at different times as indicated. The reaction products were analyzed on 8% (A) and 25% (B) urea-polyacrylamide gels for full-length and aborted transcripts, respectively.
  • Figure 6 gal transcription from minicircle DNA templates carrying the wild type gal promoter, pSA509, (lanes 1-5) and mutant gal promoter, pSA515, (lanes 6-10).
  • the reaction conditions are the same as in Figure 3.
  • the top panel (A) shows the full-length transcripts on an 8% gel urea-polyacrylamide and the bottom panel (B) g shows aborted transcripts on a 25 % urea-polyacrylamide gel.
  • FIG. 7 Lac repressor (Lacl + ) was titrated in vitro in the presence of absence or 0.2 mM cAMP. CRP was present at 100 nM in all lanes. The transcription products were displayed on an 8% (panel A) and a 25% (panel B) denaturing urea- polyacrylamide gel. The control reactions were carried out in the presence of 1 mM IPTG. The full length transcripts (panel A) were quantified using a beta- scanner, and the fraction of RNA in each lane compared to RNA made in the presence of IPTG, was plotted as a function of Lac repressor concentration (panel C). Open circles represent PI activity and closed circles represent P2 activity.
  • Figure 8 The mutant Lac repressor (LacP*) was titrated in vitro in the presence or absence of 0.2 mM cAMP. CRP was present at 100 nM. The transcription products displayed on an 8% (panel A) and a 25% (panel B) denaturing urea- polyacrylamide gel. The control reactions were carried out in the presence of 1 mM IPTG. The full length transcripts (panel A) were quantified using a beta- scanner, and the fraction of RNA in each lane, compared to RNA made in the presence of IPTG, was plotted as a function of Lac repressor concentration (panel C). Open circles represent PI activity and closed circles represent P2 activity.
  • FIG. 9 Gal repressor (GalR) was titrated in vitro in the presence or absence of 0.2 mM cAMP. CRP was present at 100 nM. The full length transcripts were quantified using a beta-scanner, and the amount of RNA relative to that made in the presence of the inducer (10 mM D-galactose) was plotted as a function of Gal repressor.
  • the DNA templates used in this study carried gal promoter with wild 5 type gal operators (pSA509, panel A); with wild type external operator and constitutive internal operator (pSA511, panel B); with constitutive external operator and wild type internal operator (pSA512, panel C). Open circles represent PI activity and closed circles represent P2 activity. 0
  • BOB bacterial attachment site attB'OB
  • mcs multiple restriction endonuclease sites for cloning
  • gal a DNA segment carrying the gal promoter and operator loci
  • Ter transcription termination signal
  • POP lambda phage attachment site attP'OP
  • Hindlll unique restriction site for endonuclease
  • Hindlll gene encoding ampicillin resistance.
  • minicircles 5 convenient for in vitro transcription study of individual promoters under physiological conditions.
  • the minicircles are generated in vivo by taking advantage of the mechanism of site-specific integrative recombination of bacteriophage lambda (13-15). These minicircles are supercoiled, making them natural substrates for transcription from the cloned promoter. Since these unitary 0 promoter templates do not carry any other transcription initiation sites, all aborted and full length transcripts originate from the cloned promoter, which allows direct qualitative and quantitative analysis of the transcripts by gel electrophoresis. Thus, these minicircles may be used to study various aspects of transcription, including 5 aspects of transcription initiation, e.g. idling and promoter clearance, as exemplified herein.
  • vectors which can be useful in creating source plasmids to generate supercoiled unitary promoter DNA templates of the invention include 0 those which can be modified to contain the - BOB - mcs - POP - sequences and which have the following properties: a selectable antibiotic resistance marker and multicopy in nature, e.g. pIBI24, which is exemplified herein, as well as vectors such as pBR322, and the like.
  • the supercoiled unitary promoter DNA templates of u the invention can also be made in vitro by one of the following two ways: (i) by carrying out the site-specific integrative recombination reaction in vitro with purified Int and IHF proteins, and (ii) by purifying a small DNA fragment carrying the promoter-terminator segment, and then ligating the two ends using DNA ligase in vitro.
  • these processes are laborious and are not cost-effective.
  • suitable host cells include those which contain and express, or which can be modified to contain and express, lambda Int and integration host factor (IHF) proteins, e.g. E. coli strain SA1751 which has been transformed to contain the plasmid pSA50X, a plasmid containing the attB'OB - 0 attP'OP segment, which is exemplified herein, and other similarly constructed cells.
  • IHF lambda Int and integration host factor
  • promoters which may be cloned and studied in the present invention include regulatable or non-regulatable promoters, including, but 5 not limited to, bacterial promoters, such as, for example, lac, lacUV5, Ipp, mal, and trp; bacteriophage promoters, such as, for example, lambda P R , lambda P L , ⁇ T7, ⁇ T4, and ⁇ SP6 promoters; and eukaryotic promoters, such as, for example, yeast GAL1 promoter, SV40 early or late promoter, the mouse mammary tumor virus (MMTV) promoter, and the metallothionein (MT) promoter.
  • regulatable or non-regulatable promoters including, but 5 not limited to, bacterial promoters, such as, for example, lac, lacUV5, Ipp, mal, and trp; bacteriophage promoters, such as, for example, lambda P R , lambda P L ,
  • terminators which may be cloned and used in the present invention include, but are not limited to, factor-independent or factor- dependent bacterial terminators such as, for example, rpoBC (rho-independent); bacteriophage terminators, such as, for example, lambda t u , lambda r R1 ; and 5 eukaryotic terminators, such as, for example, yeast SUP4 terminator.
  • Factor- independent terminators are particularly useful in the present invention.
  • prokaryotic terminators are used in conjunction with prokaryotic promoters and eukaryotic terminators are used in conjunction with 0 eukaryotic promoters.
  • regulatory elements examples include, but are not limited to, bacterial operators, such as, for example, gal, lac, trp, aroH, and trpR; bacterial activator sequences, such as, , c for example, the CRP binding site and OxyR binding site; and eukaryotic response ° elements and enhancers, such as, for example, glucocorticoid response element (GRE), estrogen response element (ERE), metallothionein response element (MRE), heat shock response element (HSRE), the SV40 enhancer (72 bp repeat), the immunoglobulin enhancer, and yeast upstream activator sequences (UAS).
  • GRE glucocorticoid response element
  • ERE estrogen response element
  • MRE metallothionein response element
  • HRE heat shock response element
  • the SV40 enhancer 72 bp repeat
  • the immunoglobulin enhancer yeast upstream activator sequences
  • the factors are included in the reaction mixture.
  • the reaction mixture may be used as a means of identifying such factors.
  • any of the above mentioned gene segments may be cloned into the construct of the invention in a form similar to their naturally-occurring counterparts, or they may be cloned into the construct of the invention in hybrid form.
  • hybrid segments which may be cloned include, for example, hybrid bacterial 5 promoters from different bacterial genes, e.g. the tac promoter (a combination of the trp and lac promoters); hybrid bacterial promoter and regulatory sequences, e.g. the gal promoter and the lac operator (exemplified herein); hybrid bacteriophage and bacterial gene segments, e.g.
  • T7 bacteriophage promoter and the lac operator hybrid eukaryotic (or viral) and bacterial gene segments, e.g. a SV40 promoter and the lac operator; and hybrid bacteriophage and eukaryotic (or viral) gene segments, e.g. a T7 bacteriophage promoter and the yeast galA operator or a SV40 promoter or yeast promoter and a bacteriophage polymerase coding region.
  • various terminators may be used with various other segments in the constructs of the invention.
  • the present invention may also be used to study the involvement of DNA looping in repressor action and to determine the precise stage of repressor action in vitro, as exemplified herein.
  • PI and P2 of the gal operon of E.coli supercoiled DNA minicircles which contained only the gal promoter segment and adjoining DNA control elements, followed by a bacterial terminator of the rpoC gene, were produced and employed using the methods and plasmids of the present invention (e.g. Figure 3).
  • the gal operon can be repressed not only by Gal repressor, but also by Lac repressor, provided that both bipartite gal operators are substituted by lac operators (37). Since topologically superhelical conformations of DNA have been shown to enhance the interactions between Lac repressor and other transcriptional regulatory proteins to their cognate DNA sites in the formation of DNA loops (10-12, 41, 42), the effect of repressors on gal transcription was studied using the supercoiled "minicircle" DNA templates of the present invention. The mechanism of repression of PI and P2 were investigated simultaneously using both the Gal and Lac repressors.
  • Wild type Lacl + repressor which shows DNA looping by electron microscopy (38, 46) and gel electrophoresis (45), resulted in normal repression of PI and P2 on a gal DNA template containing lac operators, whereas LacP*, a non-looping Lac repressor mutant, showed incomplete repression of PI and no repression of P2.
  • Gal repressor has been suggested to inhibit transcription from the gal promoters at a post RNA polymerase binding step (8, 39).
  • the use of the purified system of the invention has shown that the wild type Lac repressor established complete repression of not only full length, but also aborted transcripts (Figure 7B), which implied that the repressor inhibited the first phosphodiester bond formation or a step prior to that, i.e., the formation or the activity of the initial transcribing complex (ITC) (7) in the gal system. 5 Interestingly, the repression of gal DNA expression by GalR + repressor was incomplete in the purified transcription assay of the present invention.
  • Gal repressor is different from Lac repressor which can be tetramerized by itself
  • LacI ⁇ used in this invention is missing the C- " terminal end containing the leucines.
  • Gal repressor does not appear to have the corresponding leucines. Since the dimeric Lac"", unlike GalR + , fails to repress in vivo, it appears that the proposed looping-aid for GalR + does not help Lac"".
  • Gal repressor has been shown to cause a 10% decrease in the open complex formation at PI with a
  • the present invention has demonstrated that (1) the two gal promoters have different rate limiting steps of transcription initiation by RNA polymerase; (2) cAMP «CRP switches the gal promoter activities in the same c quantitative fashion as in vivo (19); (3) repression of gal operon occurs at a step prior to first phosphodiester bond formation; (4) repression of gal operon in vitro requires an interaction between repressors bound to two operators; and (5) while Lac repressor repressed both PI and P2, repression by Gal repressor, as opposed to the in vivo result, is incomplete for PI and is totally ineffective for P2.
  • Component(s) or conditions that aid Gal repressor in DNA looping remain to be identified. These component(s) or conditions may be determined by assaying the transcripts obtained after supplementing and/or altering the reaction mixtures containing minicircles of the present invention.
  • a plasmid vector called pSA508, was constructed (see Figure 1). This vector contained a DNA segment with multiple cloning sites (mcs) and a transcription termination sequence (Ter) between the phage lambda attachment site, attP'OP and the corresponding bacterial attachment site, attB'OB.
  • mcs multiple cloning sites
  • Ter transcription termination sequence
  • AttB'OB and attP'OP sites were produced in the orientation described herein.
  • the arrangement of attB'OB and attP'OP in that particular order produced a DNA minicircle that carried attBOP'. u If the arrangement had been attBOB' and attPOP', as is normally found in phage lambda (33), the product minicircle would have carried the attB'OP site.
  • the "P" component of attB'OP carries multiple promoters (27, 28) and would not have been serviceable in the present invention (see Figures 2 and 4).
  • pSA508 was derived from pIBI24 (International Biotechnologies, Inc.) by inserting the following DNA elements between its EcoRl and Hindlll sites in the order as follows: the 46 bp bacterial attachment site attB'OB (from -19 to +26, ref. 20), a 49 bp mcs, the 54 bp Rho-independent transcription terminator of the rpoBC operon of E. coli,
  • Plasmid pSA509 (see Figures 3 and 10) contained a 288 base pair segment of the gal promoter (-197 to +91; ref. 23) cloned between the EcoRl and PstI sites in mcs of pSA508. This DNA fragment was obtained by amplifying the
  • _ n product (i.e. minicircle or miniplasmid) was approximately 0.4 kb in size and contained the mcs and the terminator.
  • Plasmid pSA515 was identical to the pSA509 except that it carried an A:T to T:A transversion at the -11 position relative to the PI transcription initiation site (16).
  • the minicircles from pSA509 and pSA515 each contained 688 35 bp.
  • the recombinant region of each plasmid was confirmed by DNA sequencing using standard methods.
  • Recombinant substrate plasmids pSA508, pSA509 and pSA515, were introduced into __.. coli strain SA1751 [int + xis439cIS57(cro-chlA) m ] by transformation at 32°C.
  • SA1751 is E. coli K-12 strain
  • the int + gene expression from the cryptic prophage is under the control of temperature sensitive prophage repressor, cl857.
  • SA1751 containing a parental plasmid grown to late log phase at 32°C to accumulate substrate plasmid was shifted to 42 °C for 10 minutes to induce briefly Int synthesis from the cryptic lambda prophage by inactivating the thermolabile repressor, and then cooled to 32°C. After 30 minutes at the lower temperature, the cells were harvested. The rationale for returning the culture to the lower temperature was to prevent the thermolability of the integrative recombination (24).
  • the plasmid DNA profile resulting from the recombination showed not only the expected substrate and product plasmids but also various multimerized circles.
  • the monomer minicircles were separated in a 1 % agarose gel and extracted by electroelution in dialysis tubmg (25).
  • the extracted DNA was extensively dialyzed against 10 mM Tris acetate, pH 8.0, 0.1 mM EDTA and the DNA concentration was determined spectrophotometrically.
  • construction and functional elements of the plasmids used to generate supercoiled "minicircles" in vivo were as follows: The parental plasmid carried a multiple cloning site into which the gal promoter segment was inserted. This was followed by a transcription terminator. The promoter-terminator region was located on the plasmid between the lambda phage attachment site, attP'OP, and the corresponding bacterial site, attB'OB. DNA minicircles carrying the gal promoter followed by the transcription terminator were generated by site-specific recombination between the attP'OP and attB'OB sites in vivo in the host, SA1751, which provided the lambda Int protein and integration host factors, IHF.
  • pSA508 was the parental plasmid which contained no promoter at the multiple cloning site (see Figure 1).
  • pSA509 contained a 288 base pair segment of the gal promoter (-197 to +91) cloned between the EcoRl and the PstI site of pSA508 (23).
  • pSA510 was identical to pSA509 except that both gal operator loci, O E and O court were substituted with the consensus lac operator sequence: TTGTGAGCGCTCACAA (37) (SEQ ID NO:3).
  • pSA511 and pSA512 were also identical to pSA509 except that the internal operator locus (0_) and the external operator locus (O E ) were replaced with the lac operator sequence, respectively.
  • O E external operator locus
  • CRP was purified from an E. coli strain carrying the crp + gene on a multicopy plasmid pHA5, using FPLC.
  • RNA polymerase (100% saturated with sigma factor) was purchased from Epicentre Techniques (Madison, WI).
  • Gal repressor (GalR + ) and wild type (Lacl + ) and mutant Lac repressor (Lad*”) were purified as described previously (38, 43, 45).
  • DNA template 0.1 mM ATP, 0.1 mM GTP, 0.1 mM CTP, 0.01 mM UTP, and
  • RNA loading buffer 80% (vol/vol) deionized formamide, 1 X TBE (89 mM Tris borate, pH 8.0, 2 mM EDTA), 0.025% Bromophenol blue, 0.025% xylene cyanole.
  • the mixture was heated at 90°C for 2 minutes and electrophoresed through 8% or 25% polyacrylamide sequencing gels (40 cm x 0.4 mm) containing 8 M urea.
  • RNA transcripts were quantified by determining counts per minutes using a beta-scanner (AMBIS, San Diego, CA).
  • DNA minicircles with or without the gal promoters were generated from substrate plasmids by the mechanism of site-specific integrative recombination of phage lambda by integrase (Int) and integration host factor (IHF) as described in Example 1, Materials and Methods.
  • Int integrase
  • IHF integration host factor
  • the bacterial attB'OB site and the phage attP'OP site were placed in the constructs of the invention in a head-to-tail configuration spanning the mcs with or without promoter, such that recombination between the two att sites would release the intervening 0.4 kb long DNA segment as a circle, called a minicircle, carrying the attP'OB site, and a larger circle carrying the attB'OP site ( Figure 10).
  • the transcription terminator was situated between the mcs and the attP'OP.
  • the minicircle carried the mcs (with or without a cloned promoter) and the terminator.
  • the two att sites in the substrate plasmid were arranged in such a way that the P element of attP'OP was absent in the minicircle product.
  • the P element carried several promoter activities (27,28) that would generate, if present in the minicircles, unwanted RNA products during transcription assays.
  • Recombination was carried out as described in Example 1 , Materials and Methods.
  • the results of the recombination reactions for parental plasmid 1 - pSA508 are shown in Figure 2. There was no recombination product before heat induction of Int synthesis ( Figure 2, lane 2).
  • the supercoiled pSA508 was 3.3 kb and migrated as a monomer at a position marked SI and as a dimer at a position marked S2.
  • S2 was generated by homologous recombination.
  • the Int/IHF- mediated recombination under these conditions was sufficient to convert most of the substrates to products. A longer incubation time did not improve
  • Lanes 3 and 4 of Figure 2 show the two recombinant product circles of approximately 2.9 kb (marked “b") and approximately 0.4 kb (minicircle, marked “a”).
  • the two lanes showed, in addition, multiple ladders of discrete sizes.
  • the ladder comprising bands of ascending sizes and decreasing intensities, visible between "a” and "b” contained oligomeric forms of the minicircle.
  • another ladder of bands of ascending sizes and decreasing intensities was also observed above the larger product circle "b".
  • the latter ladder represented larger products with increasing numbers of minicircle units.
  • the promoter-free vector DNA minicircles were transcriptionally sterile; practically no full or aborted transcripts were seen in 8% or 25% polyacrylamide gels ( Figure 4 A, lanes 1-5 and 4B, lanes 1-5).
  • the DNA minicircles containing gal promoter segment yielded two distinct full-length transcripts in the absence of cAMP: a 120 nucleotide RNA from the PI promoter and a 125 nucleotide RNA from P2 promoter were seen in the 8% gel ( Figure 4A, lane 6).
  • cAMP the amount of PI transcripts increased, while the amount of P2 transcripts decreased (lanes 6-10).
  • the ga/-specific RNA bands constituted more than 90% of the total transcripts.
  • the 54 bp-long stretch of DNA containing the stem and loop structure of rpoC terminator was extremely effective in terminating transcription initiated from either gal promoter.
  • the total radioactivity of each band was quantified and plotted as a function of cAMP concentration (Figure 4C). As the concentration of cAMP increased, the P2 product decreased and was nearly undetectable at higher than 20 ⁇ M cAMP, while the PI product increased three-fold.
  • the quantitative effect of cAMP on the synthesis of full length transcripts from the two gal promoters was identical to that observed in vivo (19).
  • RNA polymerase was pre-incubated for 10 minutes with the template at 37 °C in transcription buffer as described above in "Transcription assays". Following a 1 minute heparin (100 ⁇ g/ml) challenge, the reaction was initiated with the addition of a nucleoside triphosphate mixture 5 containing radioactive UTP. The reaction was terminated at different times, and the transcripts were analyzed on 8% ( Figure 5 A) and 25% ( Figure 5B) gels. The synthesis of full length transcripts from both PI and PI reached maximum in about 3 minutes ( Figure 5A).
  • cAMP acted at a step prior to the first phosphodiester bond formation.
  • the aborted initiation assays mentioned above have shown that cAMP stimulated PI by enhancing open complex formation (29), presumably by increasing K B (30).
  • the cAMP dependent E. coli lacPl promoter as well as its cAMP independent UV5 variants (5) and the lambda P R promoter (3) can initiate the synthesis of significant amounts of aborted transcripts along with elongated transcripts at high concentrations of nucleoside triphosphates. It has been suggested that the nucleotide sequence of the downstream region of a promoter contributes to the lifetime of an idling initial transcribing complex (6, 54) and that the rates of open complex formation need not correlate with rates of synthesis of full-length transcripts (55).
  • the nucleotide sequences around the start sites of the P2 and PI transcripts are:
  • the trimer AUU made from P2 may arise under the limiting UTP concentration used in the present invention, the hexamer from P2 does not terminate at a uridine-rich area and thus must abort because of a kinetic or energetic barrier. It is also conceivable that the presence of the PI promoter 5 bp downstream from P2 makes the RNA polymerase stall while traversing through PI. The effect of PI on transcription from P2 was tested by using a PI mutant gal DNA minicircle template made from plasmid pSA515. The mutant carried an A:T to T:A transversion at the -11 position of PI, which primarily affected PI activity (16).
  • the present invention showed that the PI promoter is
  • Lac repressor forms a tetramer and represses gal operon containing the lac operators in vivo, whereas the mutant repressor is a non-tetrameric protein and fails to repress under similar conditions (38).
  • the mutant repressor exhibits normal binding to operators but fails to carry out the association of the dimer units into a tetramer as judged by electron microscopy (38, 44) and electrophoresis of operator- repressor complexes (45).
  • Figure 7 shows the effect of Lad + repressor on gal transcription in vitro in the absence (lanes 1-8) and presence (lanes 9-16) of 0.2 mM cAMP. Increasing concentrations of Lad + protein repressed PI in the absence and presence of cAMP, and P2 in the absence of cAMP ( Figure 7, lanes 1-4 and 9-12). CRP was present at 100 nM. Quantification by direct scanning of the radioactivity of the full length transcripts in the gels is shown graphically in Figure 7C.
  • Lacl + repressor was able to repress gal transcription greater than 95%. Similar repression of the aborted transcripts made from the gal promoters by the presence of LacP repressor was also observed ( Figure 7B). However, in the absence of cAMP, La "", repressed PI only about 75% and P2 less than 10% ( Figures 8A and 8B; lanes 1-4). In the presence of cAMP, PI was repressed by Lad"* by 75% (lanes 9-12). The results are shown quantitatively in Fig. 8C. The inhibition of P2 activity by cAMP «CRP was relieved slightly by Lad" 11 .
  • GalR + Gal repressor
  • PI transcripts were repressed about 80% at about 80 nM GalR + both in the presence or absence of cAMP, and P2 was not repressed in the absence of cAMP.
  • ADDRESSEE MORGAN & FINNEGAN
  • B STREET: 345 PARK AVENUE
  • MOLECULE TYPE DNA
  • HYPOTHETICAL NO
  • ORIGINAL SOURCE

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A system to construct supercoiled 'minicircle' DNA containing a single promoter by the use of the integrative recombination system of bacteriophage lambda is described. The supercoiled DNA minicircles are templates which carry a single promoter. Such minicircles serve as templates to study the steps of transcription initiation from a unitary promoter and to synthesize both full length transcripts and aborted transcripts under physiological conditions in the absence of other contamining promoter activities. The invention is directed to in vitro transcription of promoters, such as the E. coli gal promoter, using such minicircle DNA templates. The full-length transcripts from g^_a^_l^_ P^_1 and P^_2 promoters responded to cAMP CRP in a manner identical to that observed in vivo. In addition, an in vitro transcription assay, using minicircle DNA containing the g^_a^_l^_ promoter with l^_a^_c^_ operators, was employed to elucidate the molecular mechanism of repression. Lac repressors, which associate into a tetramer and form a DNA loop, repressed transcription from P^_1 and P^_2, while a non-looping Lac repressor mutant failed to show normal repression of both of the g^_a^_l^_ promoters.

Description

SUPERCOILED MINICIRCLE DNA AS A UNITARY PROMOTER VECTOR
FTELD OF THE INVENTION
5
The present invention relates to the production of supercoiled DNA minicircles which can be employed in vitro as a purified system to elucidate, for example, the various aspects of transcription, namely, initiation, elongation, and termination. The present system closely resembles the molecular events which
^ occur in vivo and provides supercoiled DNA plasmid circles which carry only one promoter and which are considered as unitary promoter vectors.
BACKGROUND OF THE INVENTION
15 Transcription involves the synthesis of RNA complementary to one strand of a DNA duplex, i.e. the "template" DNA, by the enzyme RNA polymerase. Transcription can be divided into three stages: (i) initiation, (ii) elongation and (iii) termination.
Initiation of transcription begins with the binding of RNA
20 polymerase to the double-stranded DNA. During the initiation of transcription, RNA polymerase goes through at least four stages: (i) initial binding to the promoter (closed complex formation), (ii) isomerization of the closed complex to make the template strand available for base pairing with ribonucleotides (open
" complex formation), (iii) idling during which RNA oligomers are made and aborted by this initial transcribing complex and (iv) clearance of the promoter concomitant with RNA chain elongation (1-7).
During initiation of transcription, when RNA polymerase makes
30 aborted oligomers before clearing the promoter as an elongating complex, the polymerase returns to the isomerized complex and recycles the initiation reactions. During these steps, RNA polymerase undergoes a series of conformational changes that may be subject to regulation (7, 8). In vitro transcription studies have shown the synthesis of considerable amounts of aborted transcripts of less than ten u nucleotides in length by many promoters. These results have underscored the importance of the idling and promoter clearance steps, in addition to closed and open complex formation, in the regulation of transcription initiation (6, 7).
The measurement of closed complex formation and subsequent open complex formation routinely uses an abortive initiation assay (9). A regulatory assessment of the idling and the promoter clearance steps requires a transcription assay that employs a DNA template with a single promoter (i.e. a unitary promoter DNA template) so that both aborted and full length transcripts can be analyzed directly and simultaneously without interference by the products of other promoters. Since topological conformation of DNA can greatly influence the interactions between DNA and the transcriptional regulatory proteins (10-12, 41, 42) in that the efficiency of promoters is usually influenced by the degree of supercoiling, it would be relevant if the unitary promoter DNA template is supercoiled.
Communication between proteins bound to spatially separated DNA control elements for the purpose of controlling gene transcription by looping out the intervening DNA segment has been shown or implicated for both prokaryotic and eukaryotic systems (reviewed in 34). DNA looping participates in repression as well as in activation of transcription initiation. An activator or a repressor can potentially modulate transcription from a promoter at the level of (i) RNA polymerase (or an activator protein) binding, (ii) RNA polymerase isomerization, (iii) formation of the initial phosphodiester bonds, or (iv) promoter clearance by RNA polymerase (7, 8).
In the gal operon of Escherichia coli, two independent promoters, PI and P2, which are located 5 base-pairs apart, drive the expression of that operon (16-18). cAMP and its receptor protein (CRP) complex modulate the two promoters in opposite directions: cAMPoCRP complex stimulates the PI promoter but represses the P2 promoter. Repression of transcription from the two partially overlapping promoters, PI and P2, requires DNA looping generated by interaction of Gal repressor molecules bound to two operators, 0E and 0„ which encompass the promoters and are separated by 11 B-DNA helical turns (23, 25, ° 38). DNase competition protection experiments in the gal system have shown that Gal repressor binding to 0E and 0, does not prevent binding of RNA polymerase or of cyclic AMP-cyclic AMP receptor protein complex (CRP) which is an activator of the PI promoter (39, 40). These results indicate that Gal repressor acts at one of the latter three steps described above.
It is plausible mechanistically that a DNA loop structure "locks" the RNA polymerase at the promoter, thereby establishing repression without any direct contact between repressor and RNA polymerase. Alternatively, repression can be established through communication(s) between repressor and allosteric site(s) in the RNA polymerase as part of a nucleoprotein complex (8). Such contacts in the complex make RNA polymerase assume an idle form in repression. DNA looping juxtaposes the necessary components in a geometrically proper complex. 5 The study of the mechanism of repression of the lac promoter by
Lacl+ repressor in purified systems has led to conflicting conclusions. Although it was originally believed that Lac repressor acts at the first step by inhibiting closed complex formation in the lac operon (47), it has been suggested that with wild type lac promoter, the repressor blocks a step after the formation of a closed promoter 0 complex (48). More specifically, from studying the cAMP independent føcUV5 promoter at high concentrations of Lac repressor and RNA polymerase, Straney and Crothers (49) suggested that Lac repressor blocks the second step, the isomerization of the RNA polymerase-/αc promoter complex to an open form. In 5 contrast, Lee and Goldfarb (50) have concluded that in the /αcUV5 promoter, Lac repressor creates a kinetic barrier in the fourth step, the promoter clearance step, which leads to an idling and aborted transcript-producing RNA polymerase. Elongation occurs when RNA polymerase clears the promoter, 0 moves along the DNA, unwinds the DNA duplex to expose a new segment of the template DNA in single-stranded condition, and extends the growing RNA chain, thus forming an RNA-DNA hybrid in the unwound region, producing an elongation ternary complex. As the RNA polymerase moves, the RNA that was previously
~ t- made is displaced from the template DNA and the DNA duplex reforms in that region.
During termination of transcription, the last base is added to the RNA chain, the RNA and RNA polymerase are released from the template DNA, and the DNA duplex reforms.
SUMMARY OF THE INVENTION
The present invention provides a DNA construct, i.e. a plasmid, which is designed to contain a selectable marker, such as ampicillin resistance (Amp); the bacterial and lambda attachment sites attB and attV (i.e. BOB and
10 POP); a multiple cloning site (mcs) a DNA sequence or segment of interest cloned into the mcs, such as the promoter and transcription start site of the gal gene; and a transcriptional terminator sequence (Ter), for example, the Ter of the rpoBC operon of Escherichia coli. A linear depiction of the relevant segment of 5 the plasmid construct is as follows: - Amp - BOB - mcs - gal - Ter - POP - . The plasmid vector of the invention is introduced into a strain of bacteria which provides the lambda integrase (Int) protein and integration host factors (IHF). The integrase gene, which encodes the Int protein, is regulated by a temperature sensitive lambda repressor, c/857. As a result, no Int is produced at the 0 temperature of 32°C; however, at the temperature of 42°C, the c/857 repressor is denatured, allowing the expression of the integrase gene and the production of the Int protein. In the present invention, host bacteria containing the plasmid vector of the invention are grown at 32°C. When the temperature is elevated to 42°C, the Int
25 protein is expressed and a supercoiled DNA minicircle is created by the excision of the OB - mcs - gal - Ter - P' segment of the plasmid and is circularized by ligation of the two ends into an isolatable miniplasmid or "minicircle". The Int protein and IHF catalyze the entire process by binding to BOB and POP. Since
30 the Int protein is somewhat heat labile, the temperature of the bacterial culture is returned to 32°C from 42°C for optimal yield.
The present invention serves as a means for the analysis of the precise and specific transcriptional properties of promoter and/or terminator present
, c in the resulting minicircle DNA. The present invention also provides a method of * in vitro transcription using purified bacterial RNA polymerase, other transcription factors, and the DNA minicircle as a template.
The present invention is also applicable to the study of eukaryotic including mammalian, yeast and plant, transcription systems. For eukaryotic systems, eukaryotic promoters, initiators, terminators and/or other transcriptional elements are used in the mcs of the plasmid vector and the appropriate eukaryotic enzymes and/or regulatory factors are supplied in the transcription reaction mixture.
The present invention is also applicable to the study of hybrid, homologous or heterologous, prokaryotic and eukaryotic transcription systems. For hybrid systems, combinations of eukaryotic or prokaryotic promoters, initiators, terminators and/or other transcriptional elements are used in the mcs of the plasmid vector and the appropriate eukaryotic and prokaryotic enzymes and/or 5 regulatory factors are supplied in the transcription reaction mixture.
The invention generates supercoiled DNA miniplasmids, also called minicircles, which comprise only one promoter, or, as in the case of the gal operon, two overlapping promoters. The DNA minicircles are frequently more efficient substrates for in vitro transcription than are linear DNA segments. A 0 supercoiled miniplasmid with unique promoter(s) can avoid the use of oligonucleotides as primers which are required to analyze promoters from both linear and circular DNA templates which contain multiple promoters.
It is an objective of the present invention to provide small
25 supercoiled DNA minicircles which are easy to make and isolate in high yields. Such supercoiled DNA minicircles are more like naturally-occurring DNA, as opposed to linear DNA fragments as templates for RNA transcription.
It is a another object of the invention to provide supercoiled DNA 30 minicircles which carry only the promoter of interest so as to alleviate any interference from other, extraneous promoters, or, for example, from an origin of replication having promoter activities, that may be present in other plasmids.
It is still another objective of the invention to generate a purified - c system in which to produce small DNA minicircles for the identification or analysis of the function of particular genes or portions of genes, preferably promoters, without competition from other genes or from other promoters, or promoter-like sequences, which may vie for the binding of RNA polymerase and which may obscure the analyses.
Another objective is to develop a DNA vector which would allow the simple detection and assay of the entire array of transcription products — both complete RNA, as well as aborted RNA oligomers, produced either by single cycle or by reiterative cycle reactions ~ in a purified system with supercoiled DNA. The supercoiled DNA minicircles carrying only one promotor followed by a terminator can yield only one full-sized RNA of discrete size for easy identification.
A further objective of the invention to provide an in vitro unitary transcription system which does not have to use oligonucleotide primers to study transcription initiation.
It is yet another objective of the invention to generate a purified system in which to produce small DNA minicircles useful as substrates for the identification and/or analyses of DNA or RNA sequences, proteins and/or other components involved in the coupling of transcription and translation. When the small DNA minicircles of the invention are used in such a manner, the appropriate enzymes and/or regulatory factors are supplied in an appropriate transcription/translation mixture.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1: Arrangement of the functional elements of the unitary promoter plasmid vector, pSA508. The symbols and abbreviations as shown on the vector construct are as follows: Xbal: unique restriction site for endonuclease Xbal; BOB: bacterial attachment site attB'OB; mcs: multiple restriction endonuclease sites for cloning; Ter: transcription termination signal; POP: lambda phage attachment site attP'OP; Hindlll: unique restriction site for endonuclease Hindlll; and Amp: gene encoding ampicillin resistance. Figure 2: DNA profiles of plasmid pSA508 before and after Int/IHF-mediated in vivo recombination displayed on a 1.0% agarose gel. Lane 1 shows the 1 kb ladder (BRL). Lane 2, plasmid DNA before recombination. Lanes 3 and 4, DNA profile of the recombination products. Lane 4 was loaded with five fold more DNA sample than lane 3 to make the minicircle product "a" clearly visible. Lane 5, the monomer DNA minicircle after purification. Arrows: a, monomer minicircle; b, the larger product circle; c, a circle with two units of larger product circle; SI, monomer substrate; and S2, dimer substrate.
Figure 3: gal promoter of E. coli in the minicircle generated from pSA509. OE and O, represent external and internal operator, respectively; Ter is the transcription terminator.
Figure 4: Effect of cAMP concentrations on transcription using the vector minicircle (from pSA508) or gal minicircle (from pSA509) as template. CRP was present at 100 nM. Transcription products were analyzed on an 8% (A) and on a 25% (B) urea-polyacrylamide gel. Lanes 1-5 in A and 1-5 in B were loaded with RNA made from vector minicircle; lanes 6-10 in A and 6-10 in B contained RNA made from gal promoter containing minicircle. The full-length transcripts on the 8% gel were quantified using a beta-scanner, and the total counts per minute (cpm) of each band were plotted against cAMP concentrations (C). The open circles represent full-length RNA made from PI; the closed circles represent full-length RNA made from P2.
Figure 5: Rate of gal RNA synthesis. A reaction mixture containing gal promoter DNA template and RNA polymerase was preincubated at 37°C for 5 min after which heparin was added to 100 μg/ml. Transcription reactions were initiated by the addition of nucleoside triphosphate substrates 1 minute after heparin challenge and were terminated at different times as indicated. The reaction products were analyzed on 8% (A) and 25% (B) urea-polyacrylamide gels for full-length and aborted transcripts, respectively.
Figure 6: gal transcription from minicircle DNA templates carrying the wild type gal promoter, pSA509, (lanes 1-5) and mutant gal promoter, pSA515, (lanes 6-10). The reaction conditions are the same as in Figure 3. The top panel (A) shows the full-length transcripts on an 8% gel urea-polyacrylamide and the bottom panel (B) g shows aborted transcripts on a 25 % urea-polyacrylamide gel.
Figure 7: Lac repressor (Lacl+) was titrated in vitro in the presence of absence or 0.2 mM cAMP. CRP was present at 100 nM in all lanes. The transcription products were displayed on an 8% (panel A) and a 25% (panel B) denaturing urea- polyacrylamide gel. The control reactions were carried out in the presence of 1 mM IPTG. The full length transcripts (panel A) were quantified using a beta- scanner, and the fraction of RNA in each lane compared to RNA made in the presence of IPTG, was plotted as a function of Lac repressor concentration (panel C). Open circles represent PI activity and closed circles represent P2 activity. Figure 8: The mutant Lac repressor (LacP*) was titrated in vitro in the presence or absence of 0.2 mM cAMP. CRP was present at 100 nM. The transcription products displayed on an 8% (panel A) and a 25% (panel B) denaturing urea- polyacrylamide gel. The control reactions were carried out in the presence of 1 mM IPTG. The full length transcripts (panel A) were quantified using a beta- scanner, and the fraction of RNA in each lane, compared to RNA made in the presence of IPTG, was plotted as a function of Lac repressor concentration (panel C). Open circles represent PI activity and closed circles represent P2 activity. Figure 9: Gal repressor (GalR) was titrated in vitro in the presence or absence of 0.2 mM cAMP. CRP was present at 100 nM. The full length transcripts were quantified using a beta-scanner, and the amount of RNA relative to that made in the presence of the inducer (10 mM D-galactose) was plotted as a function of Gal repressor. The DNA templates used in this study carried gal promoter with wild 5 type gal operators (pSA509, panel A); with wild type external operator and constitutive internal operator (pSA511, panel B); with constitutive external operator and wild type internal operator (pSA512, panel C). Open circles represent PI activity and closed circles represent P2 activity. 0
5 0 Figure 10: Arrangement of the functional elements of the unitary promoter plasmid, pSA509, and the generation of a DNA minicircle as a result of Int/IHF- mediated recombination. The symbols, abbreviations, and the details of the recombination reaction are as follows: Xbal: unique restriction site for
_ endonuclease Xbal; BOB: bacterial attachment site attB'OB; mcs: multiple restriction endonuclease sites for cloning; gal: a DNA segment carrying the gal promoter and operator loci; Ter: transcription termination signal; POP: lambda phage attachment site attP'OP; Hindlll: unique restriction site for endonuclease
Hindlll; and Amp: gene encoding ampicillin resistance.
DESCRIPTION OF THE INVENTION
One aspect of the invention is the development of a plasmid vector which generates supercoiled unitary promoter DNA templates, called "minicircles", 5 convenient for in vitro transcription study of individual promoters under physiological conditions. The minicircles are generated in vivo by taking advantage of the mechanism of site-specific integrative recombination of bacteriophage lambda (13-15). These minicircles are supercoiled, making them natural substrates for transcription from the cloned promoter. Since these unitary 0 promoter templates do not carry any other transcription initiation sites, all aborted and full length transcripts originate from the cloned promoter, which allows direct qualitative and quantitative analysis of the transcripts by gel electrophoresis. Thus, these minicircles may be used to study various aspects of transcription, including 5 aspects of transcription initiation, e.g. idling and promoter clearance, as exemplified herein.
Examples of vectors which can be useful in creating source plasmids to generate supercoiled unitary promoter DNA templates of the invention include 0 those which can be modified to contain the - BOB - mcs - POP - sequences and which have the following properties: a selectable antibiotic resistance marker and multicopy in nature, e.g. pIBI24, which is exemplified herein, as well as vectors such as pBR322, and the like. c Less preferably, the supercoiled unitary promoter DNA templates of u the invention can also be made in vitro by one of the following two ways: (i) by carrying out the site-specific integrative recombination reaction in vitro with purified Int and IHF proteins, and (ii) by purifying a small DNA fragment carrying the promoter-terminator segment, and then ligating the two ends using DNA ligase in vitro. However, these processes are laborious and are not cost-effective.
5
Examples of suitable host cells include those which contain and express, or which can be modified to contain and express, lambda Int and integration host factor (IHF) proteins, e.g. E. coli strain SA1751 which has been transformed to contain the plasmid pSA50X, a plasmid containing the attB'OB - 0 attP'OP segment, which is exemplified herein, and other similarly constructed cells.
Examples of promoters which may be cloned and studied in the present invention include regulatable or non-regulatable promoters, including, but 5 not limited to, bacterial promoters, such as, for example, lac, lacUV5, Ipp, mal, and trp; bacteriophage promoters, such as, for example, lambda PR, lambda PL, φT7, φT4, and φSP6 promoters; and eukaryotic promoters, such as, for example, yeast GAL1 promoter, SV40 early or late promoter, the mouse mammary tumor virus (MMTV) promoter, and the metallothionein (MT) promoter. 0
Examples of terminators which may be cloned and used in the present invention include, but are not limited to, factor-independent or factor- dependent bacterial terminators such as, for example, rpoBC (rho-independent); bacteriophage terminators, such as, for example, lambda tu, lambda rR1; and 5 eukaryotic terminators, such as, for example, yeast SUP4 terminator. Factor- independent terminators are particularly useful in the present invention. In general, for non-hybrid constructs, prokaryotic terminators are used in conjunction with prokaryotic promoters and eukaryotic terminators are used in conjunction with 0 eukaryotic promoters.
Examples of regulatory elements that may be cloned and studied in the present invention include, but are not limited to, bacterial operators, such as, for example, gal, lac, trp, aroH, and trpR; bacterial activator sequences, such as, , c for example, the CRP binding site and OxyR binding site; and eukaryotic response ° elements and enhancers, such as, for example, glucocorticoid response element (GRE), estrogen response element (ERE), metallothionein response element (MRE), heat shock response element (HSRE), the SV40 enhancer (72 bp repeat), the immunoglobulin enhancer, and yeast upstream activator sequences (UAS).
When any of the above mentioned promoters, terminators or regulatory elements are factor-dependent, the factors are included in the reaction mixture. Alternatively, the reaction mixture may be used as a means of identifying such factors.
Furthermore, any of the above mentioned gene segments, i.e., " promoters, terminators and regulatory elements, may be cloned into the construct of the invention in a form similar to their naturally-occurring counterparts, or they may be cloned into the construct of the invention in hybrid form. Examples of such hybrid segments which may be cloned include, for example, hybrid bacterial 5 promoters from different bacterial genes, e.g. the tac promoter (a combination of the trp and lac promoters); hybrid bacterial promoter and regulatory sequences, e.g. the gal promoter and the lac operator (exemplified herein); hybrid bacteriophage and bacterial gene segments, e.g. a T7 bacteriophage promoter and the lac operator; hybrid eukaryotic (or viral) and bacterial gene segments, e.g. a SV40 promoter and the lac operator; and hybrid bacteriophage and eukaryotic (or viral) gene segments, e.g. a T7 bacteriophage promoter and the yeast galA operator or a SV40 promoter or yeast promoter and a bacteriophage polymerase coding region. Similarly, various terminators may be used with various other segments in the constructs of the invention.
The present invention may also be used to study the involvement of DNA looping in repressor action and to determine the precise stage of repressor action in vitro, as exemplified herein. 0 To elucidate the mechanism underlying the repression of transcription initiation from the overlapping gal promoters, PI and P2 of the gal operon of E.coli, supercoiled DNA minicircles which contained only the gal promoter segment and adjoining DNA control elements, followed by a bacterial terminator of the rpoC gene, were produced and employed using the methods and plasmids of the present invention (e.g. Figure 3). These DNA minicircles, containing only gal and no other promoters, greatly facilitated investigating the mechanism of both activator (CRP) and Gal repressor action on the synthesis of both aborted and full length transcripts from the gal promoters in the same assay. These minicircles were used to study idling and promoter clearance in the gal operon of Escherichia coli.
Interestingly, the gal operon can be repressed not only by Gal repressor, but also by Lac repressor, provided that both bipartite gal operators are substituted by lac operators (37). Since topologically superhelical conformations of DNA have been shown to enhance the interactions between Lac repressor and other transcriptional regulatory proteins to their cognate DNA sites in the formation of DNA loops (10-12, 41, 42), the effect of repressors on gal transcription was studied using the supercoiled "minicircle" DNA templates of the present invention. The mechanism of repression of PI and P2 were investigated simultaneously using both the Gal and Lac repressors.
In this system, the complete transcripts from PI, an activator dependent promoter, and P2, a factor-independent promoter, were synthesized at about equal efficiencies in the absence of cAMP*CRP, in agreement with the results obtained in vivo (19) (see Figure 4). The presence of cAMP»CRP inversely regulated the activities of PI and P2. cAMP activated PI and inhibited P2 transcription (see Figure 4), also in agreement with the results obtained in vivo, thus making the system physiological and suitable for further regulatory studies.
In this system, in addition to the synthesis of the complete transcripts, excess amounts of transcription aborted after making trimers to hexamers (16). A large majority of the aborted oligomers initiated mainly at P2. Thus, this system allowed the determination of the stage at which repressor brings about inhibition of RNA synthesis in the gal system, as discussed below.
A requirement of DNA looping mediated by repressor bound to the spatially separated operator elements, OE and O„ for repression of both PI and P2 has been demonstrated in vivo (37, 38). The use of the purified system of the invention revealed that the complete repression requires an interaction of the 0 repressors bound to the operators rather than the mere occupation of the operators by the repressors. Wild type Lacl+ repressor, which shows DNA looping by electron microscopy (38, 46) and gel electrophoresis (45), resulted in normal repression of PI and P2 on a gal DNA template containing lac operators, whereas LacP*, a non-looping Lac repressor mutant, showed incomplete repression of PI and no repression of P2.
Gal repressor has been suggested to inhibit transcription from the gal promoters at a post RNA polymerase binding step (8, 39). The use of the purified system of the invention has shown that the wild type Lac repressor established complete repression of not only full length, but also aborted transcripts (Figure 7B), which implied that the repressor inhibited the first phosphodiester bond formation or a step prior to that, i.e., the formation or the activity of the initial transcribing complex (ITC) (7) in the gal system. 5 Interestingly, the repression of gal DNA expression by GalR+ repressor was incomplete in the purified transcription assay of the present invention. The PI promoter activity was repressed 80% or less, while P2 promoter activity was not inhibited at all (see Figure 9A). This behavior of GalR" resembles remarkably the pattern of repression brought about by the nontetrameric, 0 looping-defective Lac*" mutant (38) (see Figure 8), and suggests that purified GalR+ protein suffers the same non-looping property that Lad*" mutant protein possesses. Both the mutant Lac repressor and wild type Gal repressor bind to operators normally as dimers but fail to associate into a tetramer/operator complex
25 (36, 44, 45, 51). Under the conditions used in the present transcription assay, the corresponding operators are fully occupied by mutant Lac repressor and wild type Gal repressor (45, 51). Since Gal repressor has been shown to repress effectively both PI and P2 in a crude cell extract (S-30) system (52), it appears that an
30 element or a feature of the cell extract is missing in the purified system. The missing component or condition very likely aids association of dimeric repressor bound to operator to form DNA looping in the purified system. In this regard, Gal repressor is different from Lac repressor which can be tetramerized by itself
~ c through a leucine minizipper (53). LacI^ used in this invention is missing the C- " terminal end containing the leucines. Gal repressor does not appear to have the corresponding leucines. Since the dimeric Lac"", unlike GalR+, fails to repress in vivo, it appears that the proposed looping-aid for GalR+ does not help Lac"".
In the present invention, a partial repression of PI but not of P2, that was observed for GalR+ or Lad"* (see Figure 8 and Figure 9A), was also observed with Gal repressor on the gal DNA carrying an intact OE and a mutant O, (see Figure 9B). Since no repression was observed for a mutant OE and intact O, template (see Figure 9C), these results clearly showed that the partial repression of PI by GalR+ with intact operators was not the consequence of repressor interaction with both OE and d. Rather, the partial repression resulted from the occupation of OE alone by a dimeric repressor. This is in agreement with the observations made in vivo and in the crude system that an intact OE alone allowed a partial repression while intact O, alone allowed fully constitutive expression of the operon even in the
15 presence of saturating concentrations of repressor (23, 52). Apparently, this partial repression does not involve the DNA loop.
In the aborted transcription initiation assay, Gal repressor has been shown to cause a 10% decrease in the open complex formation at PI with a
? _ concomitant and similar amount of increase at P2 both in the absence and presence of cAMP»CRP (30). Consistent with the results obtained from the present invention, the minor repression of PI and activation of P2 by Gal repressor needs only an intact OE. The weak repression of PI achieved by Gal repressor or LacI"1" repressor, as was observed in the absence of DNA looping, may not be through a
25 completely different mechanism. In the framework of the repressor-RNA polymerase contact model described above, it is likely that RNA polymerase bound to PI contacts the repressor bound to OE, but the repressive contact signal, in the absence of DNA looping, is not strong enough to establish complete repression.
30 As discussed above, using supercoiled minicircles that carry the gal promoter segment, the present invention has demonstrated that (1) the two gal promoters have different rate limiting steps of transcription initiation by RNA polymerase; (2) cAMP«CRP switches the gal promoter activities in the same c quantitative fashion as in vivo (19); (3) repression of gal operon occurs at a step prior to first phosphodiester bond formation; (4) repression of gal operon in vitro requires an interaction between repressors bound to two operators; and (5) while Lac repressor repressed both PI and P2, repression by Gal repressor, as opposed to the in vivo result, is incomplete for PI and is totally ineffective for P2.
Component(s) or conditions that aid Gal repressor in DNA looping remain to be identified. These component(s) or conditions may be determined by assaying the transcripts obtained after supplementing and/or altering the reaction mixtures containing minicircles of the present invention.
The invention is further described by, but is not intended to be not limited to, the following illustrative examples:
EXAMPLES EXAMPLE 1
MATERIALS AND METHODS
Construction of plasmids
To make supercoiled minicircle DNA carrying only one promoter in vivo, the site-specific integrative recombination mechanism of bacteriophage lambda was used (13, 14, 15). A plasmid vector, called pSA508, was constructed (see Figure 1). This vector contained a DNA segment with multiple cloning sites (mcs) and a transcription termination sequence (Ter) between the phage lambda attachment site, attP'OP and the corresponding bacterial attachment site, attB'OB. In the presence of lambda Int and host IHF proteins, pSA508 underwent site- specific recombination resulting in two DNA circles, similar to those as shown for pSA509 in Figure 10. In the case of pSA508, the smaller product (i.e. the minicircle or miniplasmid) was approximately 0.2 kb in size, contained the mcs and the terminator, and did not carry a promoter.
The purpose of using attB'OB and attP'OP sites in the orientation described herein was to produce a supercoiled miniplasmid containing a single promoter of choice and no other promoter. The arrangement of attB'OB and attP'OP in that particular order produced a DNA minicircle that carried attBOP'. u If the arrangement had been attBOB' and attPOP', as is normally found in phage lambda (33), the product minicircle would have carried the attB'OP site. The "P" component of attB'OP carries multiple promoters (27, 28) and would not have been serviceable in the present invention (see Figures 2 and 4). pSA508 was derived from pIBI24 (International Biotechnologies, Inc.) by inserting the following DNA elements between its EcoRl and Hindlll sites in the order as follows: the 46 bp bacterial attachment site attB'OB (from -19 to +26, ref. 20), a 49 bp mcs, the 54 bp Rho-independent transcription terminator of the rpoBC operon of E. coli,
10 GCAAATAACGTAAAAACCCGCTTCGGCGGGTITTΓTTATGGGGGGAGTTT
AGGG (21) (SEQ ID NO: l), and the 408 bp attP'OP originating from pPH54 (from +247 to -160; ref. 22). The 156 bp sequence from the attB'OB to the transcription terminator was synthesized using a 380B DNA synthesizer (Applied 15 Biosystems). The DNA sequence of the 156 bp DNA fragment is shown below:
AATTTCTAGA CCTTCCCGTT TCGCTCAAGT TAGTATAAAA AAGCAGGCTT CAACCGAGCT CGTCGACCCG GGTACCGAGC ATGCATGAAT TCGTCTGCAG CAAATAACGT AAAAACCCGC TTCGGCGGGT TTTTTTATGG GGGGAGTTTA GGGATC (Seq. ID No:2) 20
Plasmid pSA509 (see Figures 3 and 10) contained a 288 base pair segment of the gal promoter (-197 to +91; ref. 23) cloned between the EcoRl and PstI sites in mcs of pSA508. This DNA fragment was obtained by amplifying the
25 corresponding segment of plasmid p291 (23) using primers containing an EcoRl site at -197 and a PstI site at +91 by polymerase chain reaction. In the presence of lambda Int and host IHF proteins, plasmid pSA509 underwent site-specific recombination resulting in two DNA circles as shown in Figure 10. The smaller
_ n product (i.e. minicircle or miniplasmid) was approximately 0.4 kb in size and contained the mcs and the terminator.
Plasmid pSA515 was identical to the pSA509 except that it carried an A:T to T:A transversion at the -11 position relative to the PI transcription initiation site (16). The minicircles from pSA509 and pSA515 each contained 688 35 bp. The recombinant region of each plasmid was confirmed by DNA sequencing using standard methods.
Preparation of minicircle DNA in vivo by lambda integrative recombination
Recombinant substrate plasmids, pSA508, pSA509 and pSA515, were introduced into __.. coli strain SA1751 [int+xis439cIS57(cro-chlA) m] by transformation at 32°C. SA1751 is E. coli K-12 strain
Figure imgf000019_0001
In this strain, the int+ gene expression from the cryptic prophage is under the control of temperature sensitive prophage repressor, cl857. To prepare DNA minicircle, SA1751 containing a parental plasmid grown to late log phase at 32°C to accumulate substrate plasmid, was shifted to 42 °C for 10 minutes to induce briefly Int synthesis from the cryptic lambda prophage by inactivating the thermolabile repressor, and then cooled to 32°C. After 30 minutes at the lower temperature, the cells were harvested. The rationale for returning the culture to the lower temperature was to prevent the thermolability of the integrative recombination (24). The ten minute heat shock (42°C) and the thirty minute incubation at 32 °C were sufficient for the expression of Int protein for maximal recombination between the attB'OB and at attP'OP elements under the conditions of the invention. Total plasmid DNA was isolated by an alkaline lysis protocol
(25). The plasmid DNA profile resulting from the recombination showed not only the expected substrate and product plasmids but also various multimerized circles.
The monomer minicircles were separated in a 1 % agarose gel and extracted by electroelution in dialysis tubmg (25). The extracted DNA was extensively dialyzed against 10 mM Tris acetate, pH 8.0, 0.1 mM EDTA and the DNA concentration was determined spectrophotometrically.
As described above, construction and functional elements of the plasmids used to generate supercoiled "minicircles" in vivo were as follows: The parental plasmid carried a multiple cloning site into which the gal promoter segment was inserted. This was followed by a transcription terminator. The promoter-terminator region was located on the plasmid between the lambda phage attachment site, attP'OP, and the corresponding bacterial site, attB'OB. DNA minicircles carrying the gal promoter followed by the transcription terminator were generated by site-specific recombination between the attP'OP and attB'OB sites in vivo in the host, SA1751, which provided the lambda Int protein and integration host factors, IHF. The minicircles were extracted and purified by gel electrophoresis. pSA508 was the parental plasmid which contained no promoter at the multiple cloning site (see Figure 1). pSA509 contained a 288 base pair segment of the gal promoter (-197 to +91) cloned between the EcoRl and the PstI site of pSA508 (23). pSA510 was identical to pSA509 except that both gal operator loci, OE and O„ were substituted with the consensus lac operator sequence: TTGTGAGCGCTCACAA (37) (SEQ ID NO:3). pSA511 and pSA512 were also identical to pSA509 except that the internal operator locus (0_) and the external operator locus (OE) were replaced with the lac operator sequence, respectively. In the experiments of Figure 9, an OL allele served as an Oc allele for Gal repressor.
Proteins
CRP was purified from an E. coli strain carrying the crp+ gene on a multicopy plasmid pHA5, using FPLC. RNA polymerase (100% saturated with sigma factor) was purchased from Epicentre Techniques (Madison, WI). Gal repressor (GalR+) and wild type (Lacl+) and mutant Lac repressor (Lad*") were purified as described previously (38, 43, 45).
Transcri .pti .on assays
Transcription reactions were carried out as described herein. 2 nM
DNA template, 0.1 mM ATP, 0.1 mM GTP, 0.1 mM CTP, 0.01 mM UTP, and
10-20 μCi 5' (α"32P) UTP (1 Ci = 37 GBq) were preincubated in transcription buffer (20 mM Tris acetate, pH 7.8, 10 mM magnesium acetate, 100 mM potassium glutamate) at 37°C for 5 minutes. Transcription was initiated by the addition of RNA polymerase to 20 nM in a total volume of 50 μl. To study the effect of cAMP, 100 nM CRP and different amounts of cAMP were included in the preincubation mixture. When variable components such as CRP, repressor, ° cAMP or inducer were present, they were included in the preincubation mix at concentrations described in the Description of the Drawings.
Transcription was terminated after 10 min at 37°C, unless indicated otherwise, by the addition of an equal volume (50 μl) of RNA loading buffer (80% (vol/vol) deionized formamide, 1 X TBE (89 mM Tris borate, pH 8.0, 2 mM EDTA), 0.025% Bromophenol blue, 0.025% xylene cyanole). The mixture was heated at 90°C for 2 minutes and electrophoresed through 8% or 25% polyacrylamide sequencing gels (40 cm x 0.4 mm) containing 8 M urea. RNA transcripts were quantified by determining counts per minutes using a beta-scanner (AMBIS, San Diego, CA).
EXAMPLE 2
Generation of supercoiled DNA minicircles DNA minicircles with or without the gal promoters were generated from substrate plasmids by the mechanism of site-specific integrative recombination of phage lambda by integrase (Int) and integration host factor (IHF) as described in Example 1, Materials and Methods. The bacterial attB'OB site and the phage attP'OP site were placed in the constructs of the invention in a head-to-tail configuration spanning the mcs with or without promoter, such that recombination between the two att sites would release the intervening 0.4 kb long DNA segment as a circle, called a minicircle, carrying the attP'OB site, and a larger circle carrying the attB'OP site (Figure 10). The transcription terminator was situated between the mcs and the attP'OP. Thus, the minicircle carried the mcs (with or without a cloned promoter) and the terminator. The two att sites in the substrate plasmid were arranged in such a way that the P element of attP'OP was absent in the minicircle product. The P element carried several promoter activities (27,28) that would generate, if present in the minicircles, unwanted RNA products during transcription assays. , Recombination was carried out as described in Example 1 , Materials and Methods. The results of the recombination reactions for parental plasmid 1- pSA508 are shown in Figure 2. There was no recombination product before heat induction of Int synthesis (Figure 2, lane 2). The supercoiled pSA508 was 3.3 kb and migrated as a monomer at a position marked SI and as a dimer at a position marked S2. S2 was generated by homologous recombination. The Int/IHF- mediated recombination under these conditions was sufficient to convert most of the substrates to products. A longer incubation time did not improve product formation.
The substrates and products of recombination were analyzed by restriction nuclease digestion. Lanes 3 and 4 of Figure 2 show the two recombinant product circles of approximately 2.9 kb (marked "b") and approximately 0.4 kb (minicircle, marked "a"). However, the two lanes showed, in addition, multiple ladders of discrete sizes. The ladder comprising bands of ascending sizes and decreasing intensities, visible between "a" and "b" contained oligomeric forms of the minicircle. Interestingly, another ladder of bands of ascending sizes and decreasing intensities was also observed above the larger product circle "b". The latter ladder represented larger products with increasing numbers of minicircle units. Arrow "c" points to the dimer of the larger product circle, and the ladder above represented the same with increments of the minicircle unit. The ladders were not generated by catenation, but rather by covalent additions of minicircles, as determined by restriction enzyme analysis. The above- described system generated a ladder of supercoiled circles of increasing sizes as determined by gel electrophoresis. Such ladders are useful to create size markers in gel electrophoresis for analysis of supercoiled circles. The following events resulted in the generation of the ladders: first,
Int/IHF-mediated intermolecular attB'OB x attP'OP recombinations produced parental oligomeric substrates. Next, such oligomers underwent stepwise intramolecular attB'OB x attP'OP, attP'OP x attP'OB, or attP'OB x attP'OB recombination. The Int-mediated recombination between these three pairs of att sites is considerably efficient in vivo (26). The employment of a recA- host for generation of minicircles did not reduce the oligomerization of the products (data not shown). The monomer minicircles, generated in vivo, were easily obtained in sufficient quantity for use in transcription assays. EXAMPLE 3 cAMP effect on gal transcription
Transcription initiated from the gal promoters was monitored in the presence of excess CRP (100 nM) and varying concentrations of cAMP using DNA minicircles containing a wild type gal promoter segment generated from plasmid pSA509. Minicircles containing no promoter generated from vector plasmid pSA508 were used as control DNA templates. The transcription products were analyzed on 8% and 25% denaturing polyacrylamide gels for visualizing the full length and aborted transcripts, respectively (Figure 4 A and B).
The promoter-free vector DNA minicircles were transcriptionally sterile; practically no full or aborted transcripts were seen in 8% or 25% polyacrylamide gels (Figure 4 A, lanes 1-5 and 4B, lanes 1-5). The DNA minicircles containing gal promoter segment, on the other hand, yielded two distinct full-length transcripts in the absence of cAMP: a 120 nucleotide RNA from the PI promoter and a 125 nucleotide RNA from P2 promoter were seen in the 8% gel (Figure 4A, lane 6). In the presence of increasing concentrations of cAMP, the amount of PI transcripts increased, while the amount of P2 transcripts decreased (lanes 6-10). The ga/-specific RNA bands constituted more than 90% of the total transcripts. The 54 bp-long stretch of DNA containing the stem and loop structure of rpoC terminator was extremely effective in terminating transcription initiated from either gal promoter. The total radioactivity of each band was quantified and plotted as a function of cAMP concentration (Figure 4C). As the concentration of cAMP increased, the P2 product decreased and was nearly undetectable at higher than 20 μM cAMP, while the PI product increased three-fold. The quantitative effect of cAMP on the synthesis of full length transcripts from the two gal promoters was identical to that observed in vivo (19).
EXAMPLE 4
Abortive transcription from the gal promoters
Analysis of the transcription products on a 25% polyacrylamide gel showed the synthesis of large amounts of oligomeric transcripts from the gal ° promoters described previously (Figure 4B, lanes 6-10, ref. 16). Dimers, trimers, and hexamers were the major products. The intensities of trimers and hexamers, as well as the minor tetramers, were inversely proportional to the concentration of cAMP, suggesting that they originated from P2. The pentamer, although made in much smaller amounts, showed a doublet. Its two members responded differently toward cAMP: the upper pentamer decreased while the lower one increased with increasing concentrations of cAMP, suggesting that their origins were from P2 and PI, respectively. The slightly different mobilities of the pentamers from PI and P2 are very likely the result of the differences in their nucleotide compositions. The dimers and heptamers are also believed to be a mixture of transcripts originating from both PI and P2. The bands seen at the bottom of the gel for both vector and gal promoter containing minicircles represented the unincorporated radioactive UTP. Mutant templates were used to confirm the assignment of the 5 respective oligomers to P2 and PI promoters. In a PI mutant template, the synthesis of aborted transcripts assigned to P2 based on cAMP sensitivity remained intact, while that attributed to PI disappeared (see below).
The analysis of products of a single-round of transcription was used n to determine whether the RNA oligomers were mostly precursors of the full length transcripts or were aborted transcripts. RNA polymerase was pre-incubated for 10 minutes with the template at 37 °C in transcription buffer as described above in "Transcription assays". Following a 1 minute heparin (100 μg/ml) challenge, the reaction was initiated with the addition of a nucleoside triphosphate mixture 5 containing radioactive UTP. The reaction was terminated at different times, and the transcripts were analyzed on 8% (Figure 5 A) and 25% (Figure 5B) gels. The synthesis of full length transcripts from both PI and PI reached maximum in about 3 minutes (Figure 5A). Similarly, oligomers originating from both PI and P2 0 followed the same kinetics as full-length transcripts — their synthesis increased up to 3 minutes (Figure 5B). The continuous synthesis of aborted and full length transcripts at the same rate in the same relative amounts for 3 minutes in the presence of heparin suggests that transcription initiation by the open complexes at 5 the gal promoters is a slow process. The initial transcribing complexes frequently ° aborted RNA synthesis and returned to open complexes.
EXAMPLE S
Differences in the behavior of the gal promoters
Although it is difficult to precisely determine the microscopic constants, KB and kf, for PI and P2 because of overlapping and the competitive nature of the two promoters, PI appears to be defective in KB and P2 is limiting in kf (29). But, open complexes were formed at the two promoters at comparable efficiencies in the absence of cAMP. Herbert et al. (29) reported that the ratio of KB x kf for PI and P2 is roughly 1:1, whereas the same ratio determined by Goodrich and McClure (30) is 1:3. In the presence of cAMP, the ratio changed to greater than 50:1 in favor of PI. In the direct transcription assay of the invention, it was found that in the absence of cAMP, the total amount of aborted transcripts 5 made by P2 was at least 10-fold higher than those made by PI. This measurement was obtained by determining the molar ratios of each transcript after correcting for the number of uridine residues present in each species of RNA observed in Figure 4A and 4B. Synthesis of aborted transcripts from PI and P2 is unequal in favor of P2 in the absence of cAMP, but formation of the coπesponding open complex is 0 not unequal, suggesting that the PI promoter is inefficient in the formation of the first phosphodiester bond. By comparing the molar ratios of the aborted to the full-length transcripts, it was found in the present invention that greater than 90% of transcription that initiated at PI cleared the promoter, resulting in the synthesis 5 of full-length transcripts in the presence of 100 μM ATP, GTP, CTP, and 10 μM UTP. Nierman and Chamberlin (31) have shown that productive elongation of RNA chain is a much more frequent event than dinucleotide formation in the A 1 promoter phage T7, and Levin et al. (6) have subsequently demonstrated that the 0 synthesis of 6-, 7-, and 8-mer RNA occurs at about the same rate as the production of full-length transcripts form the same promoter. However, greater than 90% of the transcription that initiated at P2 aborted. Thus, RNA polymerase idled a lot more at P2 than at PI. This demonstrated that the enzyme encountered a barrier
, c to promoter clearance at the P2 promoter. The presence of cAMP, which inhibited both aborted and full length RNA synthesis from P2, and enhanced RNA synthesis from PI, did not alter the ratio of aborted to full length transcripts from PI. Thus, cAMP acted at a step prior to the first phosphodiester bond formation.
The aborted initiation assays mentioned above have shown that cAMP stimulated PI by enhancing open complex formation (29), presumably by increasing KB (30). The cAMP dependent E. coli lacPl promoter as well as its cAMP independent UV5 variants (5) and the lambda PR promoter (3) can initiate the synthesis of significant amounts of aborted transcripts along with elongated transcripts at high concentrations of nucleoside triphosphates. It has been suggested that the nucleotide sequence of the downstream region of a promoter contributes to the lifetime of an idling initial transcribing complex (6, 54) and that the rates of open complex formation need not correlate with rates of synthesis of full-length transcripts (55). The nucleotide sequences around the start sites of the P2 and PI transcripts are:
TTATGCTATGGTTATTTCATACCATAA (SEQ ID NO:4)
P2-
Pl-
Although it is possible that the trimer AUU made from P2 may arise under the limiting UTP concentration used in the present invention, the hexamer from P2 does not terminate at a uridine-rich area and thus must abort because of a kinetic or energetic barrier. It is also conceivable that the presence of the PI promoter 5 bp downstream from P2 makes the RNA polymerase stall while traversing through PI. The effect of PI on transcription from P2 was tested by using a PI mutant gal DNA minicircle template made from plasmid pSA515. The mutant carried an A:T to T:A transversion at the -11 position of PI, which primarily affected PI activity (16). The results of synthesis of full-length RNA from this mutant as analyzed on an 8% gel are shown in Figure 6A. In the absence of cAMP, the mutation reduced P2 activity less than two-fold, but inhibited PI u activity severely; the full-length PI transcript in the PI mutant was less than 10% of wild type. However, the response to cAMP»CRP was unaltered. In the presence of 20 μM cAMP, P2 RNA was undetectable and the residual PI RNA reached maximum as was shown above for wild type. The synthesis of aborted transcripts was shown in 25% gels (Figure 6B). At cAMP concentrations of 0 and 0.2 μM, the full-length PI transcript was undetectable in the PI mutant; under these conditions, the pattern and amount of aborted transcripts from P2 were identical to those from wild type gal DNA, suggesting that the generation of aborted transcripts from P2 was independent of at least PI activity. Although it remains to be seen whether or not the actual DNA sequence of the PI region enhances idling at P2, as suggested by Levin et al. (6), the idling of RNA polymerase and aborted cycling of transcription from P2 were specific and were likely to be an intrinsic property of the P2 promoter. The biological significance
15 of a barrier to promoter clearance, if any, in the initiation of transcription at galPl remains to be demonstrated. It has been suggested that the mάlT promoter of E. coli may be regulated at this level by cAMP (32).
In summary, the present invention showed that the PI promoter is
«n limiting in closed complex and initial transcribing complex formation, while the P2 promoter is slow in isomerization and promoter clearance. In spite of the intrinsic and major differences in the nature of limiting steps of RNA polymerase for transcription initiation at the two gal promoters, complete transcripts were synthesized at about equal efficiencies from PI and P2 in the absence of cAMP.
25 The transcripts were synthesized almost exclusively from PI, at 3.5-fold stimulation, in saturating concentrations of cAMP (Figure 4C) in the transcription assays of the present invention. Since the supercoiled minicircle transcription system of the present invention duplicated the in vivo situation (19), it provides a
30 simple and physiologically appropriate system for studying all of the steps, including idling and promoter clearance, for any promoter and its regulatory aspects.
35 EXAMPLE 6
Repression of gal transcription by wild type and mutant Lac repressors
Repression of gal transcription was studied using minicircle gal DNA template (pSA510), containing lac operator sequences in place of the gal operators at OE and O, (O and OV, respectively) (37). Two types of Lac repressor were used to study repression: wild type Lad+ and mutant Lac"* repressors. Wild type Lac repressor forms a tetramer and represses gal operon containing the lac operators in vivo, whereas the mutant repressor is a non-tetrameric protein and fails to repress under similar conditions (38). The mutant repressor exhibits normal binding to operators but fails to carry out the association of the dimer units into a tetramer as judged by electron microscopy (38, 44) and electrophoresis of operator- repressor complexes (45). Figure 7 shows the effect of Lad+ repressor on gal transcription in vitro in the absence (lanes 1-8) and presence (lanes 9-16) of 0.2 mM cAMP. Increasing concentrations of Lad+ protein repressed PI in the absence and presence of cAMP, and P2 in the absence of cAMP (Figure 7, lanes 1-4 and 9-12). CRP was present at 100 nM. Quantification by direct scanning of the radioactivity of the full length transcripts in the gels is shown graphically in Figure 7C. Lacl+ repressor was able to repress gal transcription greater than 95%. Similar repression of the aborted transcripts made from the gal promoters by the presence of LacP repressor was also observed (Figure 7B). However, in the absence of cAMP, La "", repressed PI only about 75% and P2 less than 10% (Figures 8A and 8B; lanes 1-4). In the presence of cAMP, PI was repressed by Lad"* by 75% (lanes 9-12). The results are shown quantitatively in Fig. 8C. The inhibition of P2 activity by cAMP«CRP was relieved slightly by Lad"11. This was more apparent for the aborted transcripts (trimer and hexamer) from P2 (Figure 8B, lanes 1-4 and 9-12). The repression of PI and P2 by LacPand the weak repression of PI by La "" were totally relieved by the addition of 1 mM IPTG, which inactivates Lac repressors, showing that the inhibition of transcription was Lac repressor specific (lanes 5-8 and 13-16 in Figures 7 and 8). The repression by LacP was almost complete in every case with half maximal repression obtained at approximately 10 nM repressor (Figure 7C). The maximal repression of PI ϋ transcript by Lac"" of only 75 % required very high repressor concentration (90 mM) with a half-maximal concentration of about 60 nM (Figure 8C). Further increase of Lad"* repressor concentration had a nonspecific inhibitory effect: the inducer (IPTG) failed to derepress.
Property of Gal repressor
The effect of Gal repressor (GalR+) on transcription was investigated in vitro in the absence or presence of 0.2 mM cAMP using the minicircle DNA template containing wild type gal operators (pSA509, see Figure 3) at OE and O, (Oi and Oϊ, respectively). CRP was present at 100 nM. The synthesis of both full length and aborted gal RNA was investigated under these conditions. Quantification of the full length transcripts is shown in Figure 9A. In the presence of cAMP, when only PI is transcribed, approximately 80 nM GalR+ was able to reduce the PI transcripts only about 80% (right hand panel). P2 transcripts, both aborted and full length, were undetectable in the presence of cAMP but increased slightly with increasing concentration of GalR+. In the absence of cAMP, the RNA band from PI was reduced by GalR+ about 60% (left hand panel). Thus, a significant amount of gal transcription from PI was maintained in the presence of saturating concentrations of GalR+ ^respective of the presence of cAMP. P2 activity was not repressed by GalR+. In fact, P2 activity, both in the absence and in the presence of cAMP, increased slightly. The poor repressive effects of GalR+ on PI in the absence and presence of cAMP were abolished by the addition of 10 mM D-galactose.
EXAMPLE 7
Mutant operators The amount of partial repression by GalR+ repressor described above was roughly equivalent to that obtained in vivo with an intact OE (Oi) and mutant O, (O"r) (37). In order to investigate whether the partial repression in the purified system was due to an interaction between GalR+ and OE (Oi) alone, DNA 5 minicircle templates with mutations at either Oi or OE were used to determine the nature of repression with GalR+ in vitro. Figure 9B shows the effect of GalR+ concentrations on the repression of transcription using minicircle DNA (pSA511) with the genotype Of Of. This mutant DNA (pSA511) and the wild type DNA
(pSA509) provided results that were more or less indistinguishable from each other: PI transcripts were repressed about 80% at about 80 nM GalR+ both in the presence or absence of cAMP, and P2 was not repressed in the absence of cAMP.
The gal O O? DNA (ρSA512), showed no discemable effect on PI and P2 (Figure
9C). Even in the presence of very high GalR+ concentrations, very little change of gal RNA synthesis was observed either in the absence or in the presence of cAMP.
LIST OF REFERENCES
1. Walker, G., Zillig, W., Palm, P. & Fuchs, E. (1967) Eur. J. Biochem. 3,
194-201. 2. Chamberlin, M. J. (1974) Ann. Rev. Biochem. 43, 771-775.
3. McClure, W. R., Cech, C. L. & Johnston, D. E. (1978) J. Biol. Chem. 253, 8941-8948.
4. Carpousis, A. J. & Gralla, J. D. (1980) Biochemistry 19, 3245-3253. 5. Munson, L. M. & Reznikoff, W. S. (1981) Biochemistry 20, 2081-2085.
6. Levin, J. R., Krummel, B. & Chamberlin, M. J. (1987) J. Mol. Biol.
196, 85-100.
7. Krummel, B. & Chamberlin, M. J. (1989) Biochemistry 28, 7827-7842.
8. Adhya, S. (1989) Ann Rev. Genet. 23, 227-250.
9. McClure, W. R. (1985) Ann. Rev. Biochem. 54, 171-204.
10. Kramer, H., Amouyal, M., Nordheim, A., Muller-Hill, B. (1988) EMBO J. 7, 547-556.
11. Meiklejohn, A. L. & Gralla, J. D. (1989) J. Mol. Biol. 207, 661-673.
12. Hahn, S., Hendrickson, W. & Schleif, R. (1986) J. Mol. Biol. 188, 355-367. 13. Campbell, A. M. (1962) Adv. Genet. 11, 101-145. 14. Nash, H. (1981) Ann. Rev. Genet. 15, 143-167.
15. Bliska, J. B. & Cozzarelli, N. R. (1987) J. Mol. Viol. 194, 205-218.
16. Musso, R. E., DiLauro, R., Adhya, S. & de Crombrugghe, B. (1977) Cell 12, 847-854. 17. Adhya, S. & Miller, W. (1979) Nature 279, 492-494.
18. Aiba, H., Adhya, S. & de Crombrugghe, B. (1981) J. Biol. Chem. 265, 11905-11910.
19. Irani, M., Musso, R. & Adhya, S. (1987) J. Bacteriol. Ill, 1623-1630.
20. Mizuuchi, M. & Mizuuchi, K. (1985) Nucleic Acid Res. 13, 1193-1208.
21. Squires, C, Krainer, A., Barry, G., Shen, W.-F. & Squires, CL. (1981) Nucleic Acid Res. 9, 16827-16840.
22. Hsu, D.L, Ross, W. Landy, A. (1980) Nature 285, 85-91.
23. Irani, M., Orosz, L. & Adhya, S. (1983) Cell 32, 783-788.
24. Guarneros, G. & Echols, H. (1973) Virology 52, 30-38.
25. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A. & Struhl, K. eds. (1989) Current Protocols in Molecular
Biology. (Green/Wiley-Interscience, New York).
26. Echols, H. (1970) J. Mol. Biol. 47, 575-583.
27. Kravchenko, V. V., Vassilenko, S. K. & Grachev, M. A. (1979) Gene 7, 181-195.
28. Kur, J., Hasan, N. & Szybalski, W. (1989) Virology 168, 236-244.
29. Herbert, M., Kolb, A. & Buc, H. (1986) Proc. Natl. Acad. Sci. USA 83, 2807-2811. 30. Goodrich, J. A. & McClure, W. R. (1992) /. Mol. Biol. 224, 15-29.
31. Nierman, W. C & Chamberlin, M. (1979) J. Biol. Chem. 254, 7921- 7926.
32. Menendez, M., Kolb, A. & Buc, H. (1987) EMBO J. 6, 4227-4234. 33. Nash, H. (1974) Virology 57, 207.
34. Matthews, K. S. (1992) Microbiol. Rev. 56, 123-136,
35. Fritz, H.-J., Bicknase, H., Gleumes, B., Heibach, C, Roshl, S., & Ehring, R. (1983) EMBO J. 2, 2129-2135. 36. Majumdar, A. & Adhya, S. (1984) Proc. Natl. Acad. Sci. USA 81, 6100-6104.
37. Haber, R. & Adhya, S. (1988) Proc. Natl. Acad. Sci. USA 85, 9683- 9687.
38. Mandal, N., Su, W., Haber, R., Adhya, S. & Echols, H. (1990) Genes Dev. 4, 410-418.
39. Adhya, S. & Majumdar, A. (1987) in RNA Polymerase and Regulation of Transcription (Reznikoff, W., Burgess, R., Dahlberg, J., Gross, C, Record, T. & Wickens, M. eds.): pp. 129-135. 40. Kuhnke, G., Theres, C, Fritz, H.-J. & Ehring, R. (1989) EMBO J. 8, 1247-1255.
41. Browiec, J. A., Zhang, L., Sasse-Dwight, S. & Gralla, J. D. (1987) 7. Mol. Biol. 196, 101-111. 42. Lobell, R. B. & Schleif, R. F. (1991) Science 250, 528-532.
43. Majumdar, A., Rudikoff, S. & Adhya, S. (1987) J. Biol. Chem. 262, 2326-2331.
44. Lehming, N., Sartorius, J., Oehler, S., von Wilcken-Bergmann, B. & Muller-Hill, B. (1988). Proc. Natl. Acad. Sci. USA 85, 7947-7951.
45. Brenowitz, M., Mandal, N. Pickar, A., Jamison, E. & Adhya, S. (1991) J. Biol. Chem. 166, 1281-1288.
46. Kramer, H., Niemoller, M., Amouyal, M., Revet, B., Wilcken-Bergman, B. & Muller-Hill, B. (1987) EMBO J. 6, 1481-1491.
47. Nick, H. & Gilbert, W. (1985) Nature 313, 795-798.
48. de Crombrugghe, B., Chen, B., Anderson, W., Nissley, P., Gottesman, M., Pastan, I. & Perlman, R. (1971) Nature-New Biology 231, 139-142. 49. Straney, S. B. & Crothers, D. M. (1987) Cell 51, 699-707. 50. Lee, J. & Goldfard, A. (1991) Cell 66, 793-798.
51. Brenowitz, M., Jamison, E., Majumdar, A. & Adhya, S. (1990) Biochemistry 29, 3374-3383.
52. Kuhnke, G., Kraus, A., Heibach, C, Gieske, U., Fitz, H.-J. & Ehring, R. (1986) EMBO J. 5, 167-173.
53. Alberti, S., Oehler, S., Wilcken-Bergmann, B., Kramer, H. & Muller- Hill, B. (1991) New Biologists 3, 57-62.
54. Kammerer, W., Deuschle, U., Gentz, R., Bujard, H. (1986) EMBO J. 5, 2995-3000.
55. Knaus, R. and Bujard, H. (1990) In: Nucleic Acids and Molecular Biology, Eds: F. Eckstein and D.M.J. Lilly, 4, pp. 110-122.
SEQUENCE LISTING
(1) GENERAL INFORMAΗON:
(i) APPLICANTS: ADHYA, SANKAR L.; CHOY, HYON E.
(ii) TITLE OF INVENTION: SUPERCOILED MINICIRCLE DNA AS A UNITARY PROMOTER VECTOR
(iii) NUMBER OF SEQUENCES: 4
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: MORGAN & FINNEGAN (B) STREET: 345 PARK AVENUE
(C) CITY: NEW YORK
(D) STATE: NEW YORK
(E) COUNTRY: USA
(F) ZIP: 10154
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: FLOPPY DISK
(B) COMPUTER: IBM PC COMPATIBLE
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: WORDPERFECT 5.1
(vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER:
(B) FILING DATE: 16-OCT-1992
(C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: LESLIE SERUNIAN AND/OR MARY J. MORRY
(B) REGISTRATION NUMBER: 35,353 AND/OR 34,398
(C) REFERENCE/DOCKET NUMBER: 2026-4041
(ix) TELECOMMUNICATION INFORMAΗON:
(A) TELEPHONE: (212)758-4800
(B) TELEFAX: (212)751-6849
(2) INFORMATION FOR SEQ ID NO: 1 : (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 54
(B) TYPE: NUCLEIC ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: UNKNOWN
(ii) MOLECULE TYPE: DNA (iii) HYPOTHETICAL: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: E. COLI
(B) STRAIN: (C) INDIVIDUAL ISOLATE:
(D) DEVELOPMENTAL STAGE:
(E) HAPLOTYPE:
(F) TISSUE TYPE:
(G) CELL TYPE: (H) CELL LINE: (I) ORGANELLE:
(ix) FEATURE:
(A) NAME/KEY:
(B) LOCATION:
(C) IDENTIFICATION METHOD:
(D) OTHER INFORMAΗON: THE 54 BASE PAIR RHO INDEPENDENT TRANSCRIPTION TERMINATOR OF
THE RPO-BC GENE OF E. COLI
(xi) SEQUENCE DESCRIPTIONS :SEQ ID NO: 1 :
GCAAATAACG TAAAAACCCG CTTCGGCGGG TTTTTTTATG 40 GGGGGAGTTT AGGG 54
(3) INFORMAΗON FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 156 (B) TYPE: NUCLEIC ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: UNKNOWN
(ii) MOLECULE TYPE: DNA
(iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE:
(A) ORGANISM:
(B) STRAIN:
(C) INDIVIDUAL ISOLATE:
(D) DEVELOPMENTAL STAGE:
(E) HAPLOTYPE:
(F) TISSUE TYPE:
(G) CELL TYPE:
(H) CELL LINE:
(D ORGANELLE:
(ix) FEATURE:
(A) NAME/KEY: (B) LOCATION:
(C) IDENTIFICATION METHOD:
(D) OTHER INFORMATION: THE 156 BASE PAIR SEQUENCE FROM THE BACTERIAL ATT SITE TO THE TRANSCRIPTION TERMINATOR IN PLASMID PSA508
(xi) SEQUENCE DESCRIPTIONS :SEQ ID NO:2:
AATTTCTAGA CCTTCCCGTT TCGCTCAAGT TAGTATAAAA 40
AAGCAGGCTT CAACCGAGCT CGTCGACCCG GGTACCGAGC 80 ATGCATGAAT TCGTCTGCAG CAAATAACGT AAAAACCCGC 120
TTCGGCGGGT TTTTTTATGG GGGGAGTTTA GGGATC 156 (4) INFORMAΗON FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16
(B) TYPE: NUCLEIC ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: UNKNOWN
(ii) MOLECULE TYPE: DNA (iii) HYPOTHETICAL: YES
(vi) ORIGINAL SOURCE:
(A) ORGANISM:
(B) STRAIN: (C) INDIVIDUAL ISOLATE: (D) DEVELOPMENTAL STAGE:
(E) HAPLOTYPE:
(F) ΗSSUETYPE:
(G) CELL TYPE: (H) CELL LINE: (I) ORGANELLE:
(ix) FEATURE:
(A) NAME/KEY:
(B) LOCAΗON:
(C) IDENTIFICATION METHOD:
(D) OTHER INFORMAΗON: CONSENSUS LAC OPERATOR SEQUENCE
(xi) SEQUENCE DESCRIPTIONS: SEQ ID NO:3: TTGTGAGCGC TCACAA 16
(5) INFORMAΗON FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27
(B) TYPE: NUCLEIC ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: UNKNOWN
(ii) MOLECULE TYPE: DNA (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE:
(A) ORGANISM: E. COLI
(B) STRAIN:
(C) INDIVIDUAL ISOLATE:
(D) DEVELOPMENTAL STAGE:
(E) HAPLOTYPE:
(F) TISSUE TYPE:
(G) CELL TYPE:
(H) CELL LINE:
(D ORGANELLE:
(ix) FEATURE:
(A) NAME/KEY:
(B) LOCAΗON: (C) IDENTIFICAΗON METHOD:
(D) OTHER INFORMAΗON: THE NUCLEOΗDE SEQUENCES AROUND THE START SITES OF THE P2 AND PI TRANSCRIPTS OF THE GAL OPERON OF E. COLI
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
TTATGCTATG GTTATTTCAT ACCATAA 27

Claims

WHAT IS CLAIMED IS:
1. A DNA construct comprising, in the following order, a. bacterial attachment site attB'OB; b. a multiple cloning site; c. a transcription terminator; and d. lambda phage attachment site attP'OP; which, when the construct is present in a host cell containing or modified to contain genes encoding the lambda Int protein and integration host factors (IHF), recombination occurs between the attB'OB and attP'OP sites upon ^ expression of the lambda Int protein to generate a smaller supercoiled DNA minicircle comprising the multiple cloning site and the terminator.
2. The DNA construct according to claim 1 , wherein the multiple cloning site 15 further comprises a transcriptional promoter segment, wherein the transcription terminator is factor-independent, and wherein the smaller DNA minicircle comprises the terminator and the multiple cloning site containing the transcriptional promoter segment.
20
The DNA construct according to claim 2, wherein the transcriptional promoter segment comprises the gal promoter segment of the gal operon of E. coli.
4. The DNA construct according to claim 2, wherein the multiple cloning site 5 further comprises one or more operator loci operably linked to the promoter segment.
5. The DNA construct according to claim 4, wherein the operator locus 30 comprises the OE operator of the gal operon of E. coli.
6. The DNA construct according to claim 4, wherein the operator locus comprises the Oi operator of the gal operon of E. coli.
35 ° 1. The DNA construct according to claim 4, wherein the operator locus comprises the lac operator of the lac operon of __.. coli.
8. The DNA construct according to claim 4, wherein the operator loci comprise the OE and the Ox operators of the gal operon of E. coli.
9. A host cell containing the DNA construct according to claim 1.
10. The host cell according to claim 9, wherein the multiple cloning site further 0 comprises a transcriptional promoter segment, wherein the terminator is factor-independent, and wherein the smaller minicircle DNA comprises the terminator and the multiple cloning site containing the transcriptional promoter. 5
11. The host cell according to claim 9 or claim 10, wherein the gene encoding the lambda Int protein is under the control of the temperature sensitive repressor c/857.
0
12. A method for analyzing transcripts from a promoter segment on a small DNA construct, comprising the steps of:
(a) introducing a DNA construct according to claim 2 into a host cell containing or modified to contain genes encoding the
25 lambda Int protein and integration host factors (IHF);
(b) expressing the lambda Int protein, whereby a smaller DNA minicircle containing the multiple cloning site comprising the promoter segment and the transcription terminator is
30 generated by recombination between the attB'OB and attP'OP sites in the DNA construct ;
(c) harvesting the cells;
(d) isolating the smaller DNA minicircle;
» j. (e) preincubating the smaller DNA minicircle in a transcription ° mixture comprising a transcript-producing and compatible
RNA polymerase;
(f) adding ribonucleotide triphosphates to initiate a transcription reaction;
(g) terminating the transcription reaction; and (h) analyzing the RNA transcripts.
13. The method according to claim 12, further comprising adding host-cell compatible transcription initiation factors and/or transcription termination factors after the preincubation step (e), prior to or simultaneously with adding the ribonucleotide triphosphates of step (f).
14. The method according to claim 12, wherein the gene encoding the lambda Int protein is under the control of the temperature sensitive repressor c/857 and wherein expression of the Int protein comprises the steps of:
(a) growing the host cell in culture medium at 32°C to late log phase;
(b) shifting the temperature of the culture medium to 42°C for 10 minutes; and
(c) shifting the temperature of the culture medium to 32°C for 30 minutes.
15. The host cell according to claim 9, said host cell being E. coli.
16. The method according to claim 12, said host cell of step (a) being E. coli.
17. Plasmid pSA508 according to Figure 1.
18. Plasmid pSA509 according to Figure 10.
5
PCT/US1993/009918 1992-10-16 1993-10-15 Supercoiled minicircle dna as as a unitary promoter vector WO1994009127A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54059/94A AU5405994A (en) 1992-10-16 1993-10-15 Supercoiled minicircle dna as as a unitary promoter vector

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96332892A 1992-10-16 1992-10-16
US07/963,328 1992-10-16

Publications (2)

Publication Number Publication Date
WO1994009127A2 true WO1994009127A2 (en) 1994-04-28
WO1994009127A3 WO1994009127A3 (en) 1994-06-09

Family

ID=25507082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/009918 WO1994009127A2 (en) 1992-10-16 1993-10-15 Supercoiled minicircle dna as as a unitary promoter vector

Country Status (2)

Country Link
AU (1) AU5405994A (en)
WO (1) WO1994009127A2 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005297A1 (en) * 1994-08-11 1996-02-22 Boehringer Mannheim Gmbh Method of gene therapy using dna vectors without selection marker gene
WO1996026270A1 (en) * 1995-02-23 1996-08-29 Rhone-Poulenc Rorer S.A. Dna molecules, preparation thereof and use thereof in gene therapy
WO2001005961A1 (en) * 1999-07-14 2001-01-25 Clontech Laboratories, Inc. Recombinase-based methods for producing expression vectors and compositions for use in practicing the same
US6270969B1 (en) 1995-06-07 2001-08-07 Invitrogen Corporation Recombinational cloning using engineered recombination sites
WO2002083889A2 (en) * 2001-04-10 2002-10-24 Imperial College Innovations Limited Methods for the production of minicircles
US6720140B1 (en) 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US6825012B2 (en) 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
US6828093B1 (en) 1997-02-28 2004-12-07 Baylor College Of Medicine Rapid subcloning using site-specific recombination
WO2004111247A1 (en) * 2003-06-10 2004-12-23 Mologen Ag Circular expression construct for gene therapeutic applications
EP1572943A2 (en) * 2002-08-29 2005-09-14 The Board of Trustees of The Leland S. Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
US7622252B2 (en) 2005-06-10 2009-11-24 Baylor College Of Medicine Generation of minicircle DNA with physiological supercoiling
US7723077B2 (en) 2005-08-11 2010-05-25 Synthetic Genomics, Inc. In vitro recombination method
US8460924B2 (en) 2009-10-16 2013-06-11 Baylor College Of Medicine Supercoiled minivectors™ for gene therapy applications
US8497069B2 (en) 2005-04-29 2013-07-30 Synthetic Genomics, Inc. Amplification and cloning of single DNA molecules using rolling circle amplification
CN105039375A (en) * 2015-03-11 2015-11-11 戚智青 Method of establishing cloning vector through protein IHF
EP3375879A1 (en) 2017-03-14 2018-09-19 Baylor College Of Medicine Targeting minivectors to specific tissue using shape
EP3647421A1 (en) 2017-11-03 2020-05-06 Baylor College of Medicine Using minivectors to treat ovarian cancer
US11926817B2 (en) 2019-08-09 2024-03-12 Nutcracker Therapeutics, Inc. Microfluidic apparatus and methods of use thereof
EP4335924A1 (en) 2022-09-08 2024-03-13 Twister Biotech, Inc. Ultrapure minivectors for gene therapy
EP4338755A1 (en) 2022-09-07 2024-03-20 Twister Biotech, LLC Using minivectors to treat idiopathic pulmonary fibrosis
EP4357456A1 (en) 2021-10-21 2024-04-24 Twister Biotech, Inc. Treatment of liver cancer or liver fibrosis

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ525134A (en) 1999-03-02 2004-09-24 Invitrogen Corp Compositions and methods for use in recombinational cloning of nucleic acids
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
JP2007512838A (en) 2003-12-01 2007-05-24 インヴィトロジェン コーポレーション Nucleic acid molecules containing recombination sites and methods of use thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIO/TECHNOLOGY vol. 2, no. 12 , December 1984 , NATURE AMERICA, INC., NEW YORK, US; pages 1045 - 1049 K. BACKMAN ET AL. 'Use of synchronous site-specific recombination in vivo to regulate gene expression' *
GENE vol. 40, no. 1 , 1985 , ELSEVIER PUBLISHERS, N.Y., U.S.; pages 163 - 168 A.J. PODHAJSKA ET AL. 'Control of cloned gene expression by promoter inversion in vivo: construction of the heat-pulse-activated att-nutL-p-att-N module' *
GENE vol. 56, no. 1 , 1987 , ELSEVIER PUBLISHERS, N.Y., U.S.; pages 145 - 151 N. HASAN AND W. SZYBALSKI 'Control of cloned gene expression by promoter inversion in vivo; construction of improved vectors with a multiple cloning site and the ptac promoter' *
MOLECULAR BIOLOGY OF THE GENE, FOURTH EDITION 1987 , BENJAMIN/CUMMINGS PUBL. COMP. INC.,MENLO PARK, CA,US; WATSON, HOPKINS,ROBERTS STEITZ,WEINER *
PROC. NATL. ACAD SCI. vol. 85, no. 24 , December 1988 , NATL. ACAD SCI., WASHINGTON, DC, US; pages 9683 - 9687 R. HABER AND S. ADHYA 'Interaction of spatially separated protein-DNA complexes for control of gene expression: Operator conversions' cited in the application *
PROC. NATL. ACAD SCI. vol. 89, no. 23 , 1 December 1992 , NATL. ACAD SCI., WASHINGTON, DC, US; pages 11264 - 11268 H.E. CHOY AND S. ADHYA 'Control of gal transcription through DNA looping: Inhibition of the initial transcription complex' *
PROC. NATL. ACAD SCI. vol. 90, no. 2 , 15 January 1993 , NATL. ACAD SCI., WASHINGTON, DC, US; pages 472 - 476 H.E. CHOY AND S. ADHYA 'RNA polymerase idling and clearance in gal promoters: Use of supercoiled minicircle DNA template made in vivo' *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265218B1 (en) 1994-08-11 2001-07-24 Roche Diagnostics Gmbh Plasmids without a selection marker gene
WO1996005297A1 (en) * 1994-08-11 1996-02-22 Boehringer Mannheim Gmbh Method of gene therapy using dna vectors without selection marker gene
AU709111B2 (en) * 1995-02-23 1999-08-19 Gencell S.A. DNA molecules, preparation and use in gene therapy
US6143530A (en) * 1995-02-23 2000-11-07 Rhone-Poulenc Rorer S.A. Circular DNA expression cassettes for in vivo gene transfer
FR2731014A1 (en) * 1995-02-23 1996-08-30 Rhone Poulenc Rorer Sa DNA MOLECULES, PREPARATION AND USE IN GENE THERAPY
WO1996026270A1 (en) * 1995-02-23 1996-08-29 Rhone-Poulenc Rorer S.A. Dna molecules, preparation thereof and use thereof in gene therapy
US6825012B2 (en) 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
US6492164B1 (en) 1995-02-23 2002-12-10 Aventis Pharma S.A. Circular DNA expression cassettes for gene transfer
US6720140B1 (en) 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US6270969B1 (en) 1995-06-07 2001-08-07 Invitrogen Corporation Recombinational cloning using engineered recombination sites
EP1227147A2 (en) * 1995-06-07 2002-07-31 Invitrogen Corporation Recombinational cloning using engineered recombination sites
EP1229113A2 (en) * 1995-06-07 2002-08-07 Invitrogen Corporation Recombinational cloning using engineered recombination sites
EP1227147A3 (en) * 1995-06-07 2002-08-14 Invitrogen Corporation Recombinational cloning using engineered recombination sites
EP1229113A3 (en) * 1995-06-07 2002-11-27 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US6828093B1 (en) 1997-02-28 2004-12-07 Baylor College Of Medicine Rapid subcloning using site-specific recombination
US6410317B1 (en) 1999-07-14 2002-06-25 Clontech Laboratories, Inc. Recombinase-based methods for producing expression vectors and compositions for use in practicing the same
WO2001005961A1 (en) * 1999-07-14 2001-01-25 Clontech Laboratories, Inc. Recombinase-based methods for producing expression vectors and compositions for use in practicing the same
WO2002083889A3 (en) * 2001-04-10 2003-11-13 Imp College Innovations Ltd Methods for the production of minicircles
WO2002083889A2 (en) * 2001-04-10 2002-10-24 Imperial College Innovations Limited Methods for the production of minicircles
EP1572943A2 (en) * 2002-08-29 2005-09-14 The Board of Trustees of The Leland S. Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
US10612030B2 (en) 2002-08-29 2020-04-07 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
EP1572943A4 (en) * 2002-08-29 2007-06-20 Univ Leland Stanford Junior Circular nucleic acid vectors, and methods for making and using the same
US9745590B2 (en) 2002-08-29 2017-08-29 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
EP2801614A1 (en) * 2002-08-29 2014-11-12 The Board of Trustees of The Leland S. Stanford Junior University Circular nucleic acid vectors and methods for making and using the same
US7897380B2 (en) 2002-08-29 2011-03-01 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
US8124407B2 (en) 2002-08-29 2012-02-28 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
US8828726B2 (en) 2002-08-29 2014-09-09 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
WO2004111247A1 (en) * 2003-06-10 2004-12-23 Mologen Ag Circular expression construct for gene therapeutic applications
US8497069B2 (en) 2005-04-29 2013-07-30 Synthetic Genomics, Inc. Amplification and cloning of single DNA molecules using rolling circle amplification
US7622252B2 (en) 2005-06-10 2009-11-24 Baylor College Of Medicine Generation of minicircle DNA with physiological supercoiling
US11542529B2 (en) 2005-08-11 2023-01-03 Codex Dna, Inc. In vitro recombination method
US7723077B2 (en) 2005-08-11 2010-05-25 Synthetic Genomics, Inc. In vitro recombination method
US9534251B2 (en) 2005-08-11 2017-01-03 Synthetic Genomics, Inc. In vitro recombination method
US10577629B2 (en) 2005-08-11 2020-03-03 Sgi-Dna, Inc. In vitro recombination method
US8460924B2 (en) 2009-10-16 2013-06-11 Baylor College Of Medicine Supercoiled minivectors™ for gene therapy applications
CN105039375A (en) * 2015-03-11 2015-11-11 戚智青 Method of establishing cloning vector through protein IHF
EP3375879A1 (en) 2017-03-14 2018-09-19 Baylor College Of Medicine Targeting minivectors to specific tissue using shape
EP3647421A1 (en) 2017-11-03 2020-05-06 Baylor College of Medicine Using minivectors to treat ovarian cancer
US11926817B2 (en) 2019-08-09 2024-03-12 Nutcracker Therapeutics, Inc. Microfluidic apparatus and methods of use thereof
EP4357456A1 (en) 2021-10-21 2024-04-24 Twister Biotech, Inc. Treatment of liver cancer or liver fibrosis
EP4338755A1 (en) 2022-09-07 2024-03-20 Twister Biotech, LLC Using minivectors to treat idiopathic pulmonary fibrosis
EP4335924A1 (en) 2022-09-08 2024-03-13 Twister Biotech, Inc. Ultrapure minivectors for gene therapy

Also Published As

Publication number Publication date
AU5405994A (en) 1994-05-09
WO1994009127A3 (en) 1994-06-09

Similar Documents

Publication Publication Date Title
WO1994009127A2 (en) Supercoiled minicircle dna as as a unitary promoter vector
US11408020B2 (en) Methods for in vitro joining and combinatorial assembly of nucleic acid molecules
JP7208956B2 (en) Compositions and methods for high-fidelity assembly of nucleic acids
Sprengart et al. The downstream box: an efficient and independent translation initiation signal in Escherichia coli.
JP3143475B2 (en) Induced transcription of double-stranded DNA by nucleic acid analogs
US5648245A (en) Method for constructing an oligonucleotide concatamer library by rolling circle replication
Mudd et al. Processing of unstable bacteriophage T4 gene 32 mRNAs into a stable species requires Escherichia coli ribonuclease E.
US5503995A (en) Exchangeable template reaction
JP3745375B2 (en) Methods for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase
ES2381824T3 (en) Procedures for generating very diverse libraries
JP4756805B2 (en) DNA fragment synthesis method
Persson et al. Control of replication of plasmid R1: structures and sequences of the antisense RNA, CopA, required for its binding to the target RNA, CopT.
Choy et al. RNA polymerase idling and clearance in gal promoters: use of supercoiled minicircle DNA template made in vivo.
CN116732145A (en) Production of closed linear DNA
JP4455061B2 (en) Methods for reducing errors in nucleic acid populations
Balakin et al. Unusual ribosome binding properties of mRNA encoding bacteriophage λ repressor
JPH10513058A (en) Isothermal amplification method for nucleic acid molecules
JP6960684B2 (en) Method of replication or amplification of circular DNA
Xiong et al. Transcriptional slippage during the transcription initiation process at a mutant lac promoter in vivo
Frieden et al. Tightening the belt on polymerases: evaluating the physical constraints on enzyme substrate size
Russell et al. Direct introduction and transient expression of capped and non-capped RNA in Saccharomyces cerevisiae
Loayza et al. Gene 32 transcription and mRNA processing in T4‐related bacteriophages
Paillait et al. The use of chemical modification interference and inverse PCR mutagenesis to identify the dimerization initiation site of HIV-1 genomic RNA
JP2011000058A (en) Method for amplifying target dna
Villarreal et al. A general method of polymerase-chain-reaction-enabled protein domain mutagenesis: construction of a human protein S-osteonectin gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA